Pyrrolo-imidazo[1,2- a]pyridine Scaffolds through a Sequential Coupling of N -Tosylhydrazones with Imidazopyridines and Reductive Cadogan Annulation, Synthetic Scope, and Application

Kena Zhang, Abderrahman El Bouakher, Hélène Lévaïque, Jérôme Bignon, Pascal Retailleau, Mouad Alami, Abdallah Hamzé

► To cite this version:

Kena Zhang, Abderrahman El Bouakher, Hélène Lévaïque, Jérôme Bignon, Pascal Retailleau, et al.. Pyrrolo-imidazo[1,2- a]pyridine Scaffolds through a Sequential Coupling of N -Tosylhydrazones with Imidazopyridines and Reductive Cadogan Annulation, Synthetic Scope, and Application. *Journal of Organic Chemistry*, 2019, 84 (21), pp.13807-13823. 10.1021/acs.joc.9b02018 . hal-02414103

HAL Id: hal-02414103

<https://hal.science/hal-02414103>

Submitted on 16 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Pyrrolo-imidazo[1,2-*a*]pyridine Scaffolds through a Sequential Coupling of *N*-tosylhydrazones with Imidazopyridines and Reductive Cadogan Annulation, Synthetic Scope, and Application

Kena Zhang,[†] Abderrahman El Bouakher,[†] Helene Levaique,[‡] Jerome Bignon,[‡] Pascal Retailleau,[§]
Mouad Alami,^{*,†} and Abdallah Hamze^{*,†}

[†]BioCIS UMR 8076, Université Paris-Sud, CNRS, Université Paris-Saclay, Equipe Labellisée
Ligue Contre Le Cancer, Laboratoire de Chimie Thérapeutique, Faculté de Pharmacie, rue J.-
B. Clément, F-92296 Châtenay-Malabry, France

[‡]Institut de Chimie des Substances Naturelles, UPR2301, CNRS, Université Paris-Sud,
Université Paris-Saclay, Avenue de la Terrasse, F-91198 Gif-sur-Yvette, France

[§]CIBI platform, Institut de Chimie des Substances Naturelles, UPR 2301, CNRS avenue de la
terrasse, F-91198 Gif sur Yvette, France

mouad.alami@u-psud.fr ; abdallah.hamze@u-psud.fr

CORRESPONDING AUTHOR. Tel.: (+33) 1 4683-5498. Fax: (+33) 1 4683-5827.

Abstract:

A new strategy for the construction of 3-phenyl-1*H*-pyrrolo-imidazo[1,2-*a*]pyridine backbone is described. The reaction starts from the coupling between *N*-tosylhydrazones (NTH) and 2-chloro-3-nitroimidazo[1,2-*a*]pyridines leading to the formation of 3-nitro-2-(arylvinyl)imidazo[1,2-*a*]pyridine derivatives. Optimization of Cadogan-reductive conditions allowed us the conversion of the obtained nitro derivative to a new scaffold of type 3-aryl-1*H*-pyrroloimidazo[1,2-*a*]pyridine. This method provides rapid access to new libraries in the context of diversity-oriented synthesis (DOS) which intends to generate small molecules with a large structure diversity in an efficient manner. Screening of the biological activity of the newly generated compounds leads to the identification of a new hit **5cc** which exhibits good antiproliferative activity in submicromolar range against human colon cancer cell line.

Introduction

Microtubules are essential in various cellular processes, including spindle formation, cellular shape maintenance, and intracellular transport of organelles.¹ Microtubules constitute an attractive target for chemotherapeutic agents to treat cancer.² Tubulin binding agents such as natural combretastatin A-4 (CA-4) disrupted efficiently microtubules structures, and present an interesting antivasculature activity.³ CA-4 can isomerize into a thermodynamically more stable

but less active trans isomer.⁴ Recently, our efforts in the design of more stable analogs of CA-4 lead us to identify *isocombretastatin* A-4 (*isoCA-4*) with similar antiproliferative activity (Fig. 1).⁵ In continuation of our endeavors to have a better understanding of the structure-activity relationship of this series of molecules, we focus on creating compound collections based on privileged scaffolds.

Figure 1. Structures of CA-4, *isoCA-4*, *isoCarbazole*-based tubulin inhibitors and the general structure of target compounds **3** and **5**.

Recently, we identified that the carbazole moiety constitutes a valuable solution to replace the B-ring of *isoCA-4* with good activity (Fig. 1).⁶ Encouraged by these results, we planned to develop a new synthesis which permits us the generation of new scaffolds of biological interests. Imidazo[1,2-*a*]pyridines is an important biologically active moiety, with a growing interest in medicinal chemistry.⁷ They have been used as a skeleton in various drugs such as alpidem, olprinone, and zolpidem, and in many lead molecules that are now under human clinical trials.⁸ On the other hand, diversity-oriented synthesis (DOS) intends to generate small molecules with a large structure diversity has become a paradigm, providing a larger array of the chemical space in drug discovery. Also, the development of a convergent approach consisting of a complexity-generating reaction followed by cyclization steps and appendage diversity constitutes an emerging area in medicinal chemistry.⁹ In the last decade, *N*-tosylhydrazones (NTH) has emerged as a versatile coupling partner for palladium-catalyzed

cross-coupling reactions.¹⁰ From mechanistic point of view, this cross-coupling does not involve the participation of a stoichiometric organometallic species during the catalytic cycle. Thus, the use of NTH as a source of diazo compounds led to the discovery of new C-C¹¹ and C-heteroatom¹² bond-forming reactions of remarkable synthetic potential. In this context, herein, we report a synthetic method for the synthesis of new libraries of type 2-(1-arylvinyl)imidazo[1,2-*a*]pyridine **3**, and 3-aryl-1*H*-pyrrolo-imidazo[1,2-*a*]pyridine **5** (Scheme 1). This method consists of using a convergent reactional sequence: formation of *ortho*-nitro-arenes from NTH and 2-chloro-3-nitroimidazo[1,2-*a*]pyridine followed by a reductive Cadogan cyclization.

Scheme 1. Synthetic strategy for the synthesis of 2-(1-arylvinyl)imidazo[1,2-*a*]pyridine derivatives (library **A** and **B**), and Cadogan cyclization leading to the formation of 3-phenyl-1*H*-pyrrolo-imidazo[1,2-*a*]pyridine derivatives (library **C**) .

Results and discussion

Initially, 2-chloroimidazo[1,2-*a*]pyridines were synthesized in a two-step procedure from 2-aminopyridine according to Tschitschibabin procedure¹³ by condensation of 2-aminopyridine derivatives with chloroacetic acid in the presence of trimethylamine, then the imidazo[1,2-*a*]pyridin-2-ol intermediate was converted to 2-chloroimidazo[1,2-*a*]pyridine in the presence of POCl₃. Nitration of this latter compound led to the 2-chloro-3-nitroimidazo[1,2-*a*]pyridine derivatives (**2**) in good yield (For details, see experimental part).

The corresponding 3-nitro-2-(1-arylvinyl)imidazo[1,2-*a*]pyridine derivatives **3** were obtained following Pd-catalyzed coupling between NTH **1** and the corresponding 2-chloro-3-nitroimidazo[1,2-*a*]pyridine **2** in high yield (Scheme 2). The cross-coupling reaction proceeds well either with NTH having ED or EWGs to afford the corresponding 3-nitro-2-(arylvinyl)imidazopyridines **3** in good to high yields (compounds **3a-3s**). Also, the coupling tolerates the presence of functional group on the NTH (compounds **3j**, **3l**, and **3m**). Heterocyclic NTHs were also used successfully, and the corresponding compounds (**3o**, **3p**, **3r**, and **3s**) were obtained in good yields. Finally, the modification was obtained with the respect of imidazopyridine partner **2**, and compounds **3u-z** were obtained in good yield.

Next, to get more diversity of our compounds, we realized a selective reduction of some nitro compounds **3** to amino derivatives **4**, in the presence of iron and a catalytic amount of HCl, the corresponding products (**4a-g**) were obtained in excellent yield (Scheme 3).

Scheme 2. Cross-coupling between *N*-tosylhydrazones **1** and electrophilic partner **2**.^a

^a Reaction Conditions: *N*-tosylhydrazone **1** (1 mmol), substrate **2** (1 mmol), $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol%), XPhos (5 mol%), LiOtBu (2.2 mmol) in 4 mL of dioxane in a sealed tube, MW 110 °C, 30 min.

Scheme 3. Reduction of 3-nitro-2-(1-arylviny)imidazo[1,2-a]pyridine derivatives **3** to their corresponding amines **4**.^a

^a Iron powder (2 mmol) and concd HCl (ca. 1 μ L), nitro-compound (0.2 mmol), EtOH (0.5 mL), water (120 μ L), reflux for 90 min.

In order to increase the chemical diversity and generate a new library of compounds, we then took advantage of the presence of nitro group on the (arylvinyl)imidazo[1,2-*a*]pyridine derivatives **3**, to perform a reductive Cadogan cyclization leading to the generation of a novel scaffold of type of 3-aryl-1*H*-pyrrolo-imidazo[1,2-*a*]pyridine **5**.

As a model substrate, we started our optimization by performing reductive cyclization on substrate **3e** (**Table 1**). As the 3-phenyl-1*H*-pyrrolo-imidazo[1,2-*a*]pyridine has the same R, as the triphenylphosphine oxide generated during the reaction, we protected it in situ by using Boc protection to facilitate the isolation of the desired compound.

Performing the reaction in the presence of PPh₃ in dioxane or in the standard conditions of Cadogan¹⁴ (triethyl phosphite as the solvent) failed to give the desired product (entries 1-4). The presence of nitrogen atom in the structure of the imidazo[1,2-*a*]pyridine derivative seems to slow the reaction in comparison to standard deoxygenation of *ortho*-nitrostyrenes. Recently,

the iron-phenanthroline complex has been reported to catalyze the reductive cyclization of *ortho*-nitrostyrenes into indoles.¹⁵ Accordingly, we tried these optimal conditions on substrate **3e**. As described in Table 1 (entries 5-7), in our hands, only a traces of desired product was observed by using 1 mol % of Fe(OAc)₂ and 1 mol % of 4,7-(MeO)₂phen and phenylsilane as the reductant in DME (entry 5). Also, no improvement of the conversion was observed by switching from DME solvent to THF or dioxane (entries 6 and 7). Sanz and Arnaiz had developed a molybdenum-catalyzed cyclization of 2-nitrobiphenyls to carbazole.¹⁶ Conducting the reaction on substrate **3** using these reported conditions : (MoO₂Cl₂(dmf)₂) (10 mol%) in the presence of PPh₃ (2.4 equiv) in refluxing toluene or dioxane for 3 h led to a low yield of **5a**, even after the prolongation of the reaction time to 72 h, no improvement of the yield was observed (entry 8). Also, no significant increase in the yield was observed when dioxane was used as the solvent (entry 9). Increasing the amount of reducing agent from 2.4 to 4 equiv. (entry 9 vs 10), led to the formation of compound **5e**, after 72 h of heating but only, in a 40% moderate yield.

To reduce the time of this transformation, we performed the reaction in a sealed tube under microwave irradiation at 135 °C (entry 11), to our surprise, the reaction proceeds more rapidly in only 4 h, and the desired product was isolated in a synthetically useful yield of 75%. Performing the reaction in a similar conditions, in a sealed tube but without M.W irradiation (entry 12) led to compound **5e**, in only 45% yield. Although toluene could be used in place of dioxane without attenuating the yield of **5e** (entry 13).

Table 1. Optimization of the reaction conditions for the synthesis of 3-phenyl-1H-pyrrolo-imidazo[1,2-*a*]pyridine ^a

Entry	Catalyst/ ligand	Reducing agents	Solvent	T °C	time	Yield (%)
1		PPh_3	dioxane	160	2h	0
2 ^b		PPh_3	diglyme	160	2h	0
3 ^b		PPh_3	dioxane	160	48h	0
4 ^b		$\text{P}(\text{OEt})_3$	$\text{P}(\text{OEt})_3$	160	2h	0
5	$\text{Fe}(\text{OAc})_2/$ 4,7-(MeO) ₂ phen	PhSiH_3	DME	80	12h	trace
6	$\text{Fe}(\text{OAc})_2/$ 4,7-(MeO) ₂ phen	PhSiH_3	THF	80	12h	trace
7	$\text{Fe}(\text{OAc})_2/$ 4,7-(MeO) ₂ phen	PhSiH_3	dioxane	110	12h	trace
8 ^b	$\text{MoO}_2\text{Cl}_2(\text{dmf})_2$	PPh_3	toluene	110	72h	20
9 ^b	$\text{MoO}_2\text{Cl}_2(\text{dmf})_2$	PPh_3	dioxane	110	72h	22
10	$\text{MoO}_2\text{Cl}_2(\text{dmf})_2$	PPh_3	dioxane	110	72h	40
11 ^c	$\text{MoO}_2\text{Cl}_2(\text{dmf})_2$	PPh_3	dioxane	135	4h	75
12	$\text{MoO}_2\text{Cl}_2(\text{dmf})_2$	PPh_3	dioxane	135	4h	45
13 ^c	$\text{MoO}_2\text{Cl}_2(\text{dmf})_2$	PPh_3	toluene	135	4h	72

^a Reaction Conditions. **Step 1**: substrate **3a** (0.2 mmol), catalyst (10 mol%), ligand (10 mol%), reducing agent (4 equiv), in 2 mL of solvent were used, in a sealed tube. ^b 2.4 equiv of PPh_3 were used. ^c M.W irradiation was used. **Step 2**. After completion of step 1, $(\text{Boc})_2\text{O}$ (0.4 mmol), DMAP (0.04 mmol), TEA (0.6 mmol), were added at rt.

Finally, to prove the importance of M.W irradiation in this transformation, we performed the reaction in a similar condition to entry 11, but without M.W irradiation, in these conditions, compound **5e** was formed in a moderate yield of 45% proving the importance of M.W irradiation.

Next, the scope of formation of 3-phenyl-1*H*-pyrrolo-imidazo[1,2-*a*]pyridine derivatives with different substituents was evaluated under the optimized conditions (scheme 4).

The cyclization of the nitro derivatives bearing substituents on the benzene ring could be varied and both EDG (MeO, Me), and EWG (F, CN, Cl), all proceeded efficiently to lead, the corresponding products in good to excellent yield. The structure of compounds **5e**, **5s**, and **5u** was established by X-ray diffraction.¹⁷

It is noteworthy that phenyl (**5a**), naphthyl (**5b**), phenantryl (**5c**) or heterocyclic derivatives (**5o**, **5p**, **5r** and **5s**) were also identified as suitable substrates for the reaction, delivering the products in good yield. Next, the scope of the reaction was evaluated by modifying the imidazo[1,2-*a*]pyridine partner. The reaction proceeds also with trisubstituted alkenes (**3q-t**, **3y** and **3z**) under our similar conditions to give 2,3 disubstituted pyrrolo-imidazo[1,2-*a*]pyridine derivatives (**5q-t**, **5y** and **5z**). A series of substituents, including phenyl, 4-methoxyphenyl or 4-(trifluoromethyl)phenyl, on position 7 of imidazo[1,2-*a*]pyridine were evaluated, and the corresponding products were obtained in a moderate to good yield (compounds **5u-z**).

In the medicinal chemistry context, it would be interesting to dispose of the free nitrogen form of the heterocycle. To this end, we realized the deprotection of some compound using mild conditions, by heating the protected form of the pyrrolo-imidazo[1,2-*a*]pyridine in a mixture of MeOH/H₂O, and catalytic amount of trifluoroacetic acid under M.W irradiation for 30 minutes. Under these conditions, the desired compounds were obtained in a nearly quantitative yield (Scheme 4, compounds **5aa**, **5cc**, **5gg**, and **5kk**).

Scheme 4. Reductive cyclization of nitro-2-(1-phenylvinyl)imidazo[1,2-*a*]pyridine **3** to 3-phenyl-1H-pyrrolo-imidazo[1,2-*a*]pyridine derivatives **5**.^a

^aReaction Conditions: Step 1. substrate **3** (0.5 mmol), $\text{MoO}_2\text{Cl}_2(\text{dmf})_2$ (10 mol%), PPh_3 (4 equiv), in 3 mL of dioxane, in a sealed tube. MW 135 °C, 4 h. Step 2. After completion of step 1, $(\text{Boc})_2\text{O}$ (0.65 mmol), DMAP (0.1 mmol), TEA (1.5 mmol), were added at rt. ^b Deprotection step: protected heterocycle (0.5 mmol) in MeOH/ H_2O (1/3), TFA (ca. 5 μL) was heated under MW at 110 °C for 30 min.

Finally, we wished to examine the possibility to realize this transformation in a one-pot fashion, starting from NTH **1** and 2-chloroimidazo[1,2-*a*]pyridines **2**. As presented in Scheme 5, many compounds were successfully obtained, with an average of 50% yield after 3 sequential steps. This represents an average of ~ 80% for each step of this transformation.

Scheme 5. Substrate scope of the one-pot cross-coupling between *N*-tosylhydrazones **1** and 2-chloro-3-nitroimidazo[1,2-*a*]pyridine **2**.^a

^a Reaction Conditions: Step 1. *N*-tosylhydrazone **1** (1 mmol), substrate **2** (1 mmol), $\text{Pd}_2\text{dba}_3 \cdot \text{CHCl}_3$ (2.5 mol%), XPhos (5 mol%), LiOtBu (2.2 mmol) in 4 mL of dioxane in a sealed tube, MW 110 °C, 30 min. Then $\text{MoO}_2\text{Cl}_2(\text{dmf})_2$ (10 mol%), PPh_3 (4 equiv), were added, and the mixture was irradiated at 135 °C for 4 h. Step 2. After completion of step 1, $(\text{Boc})_2\text{O}$

(1.3 mmol), DMAP (0.2 mmol), TEA (mmol), were added and the mixture was stirred at rt for 2 h.

Mechanism

On the basis of the work of Faza *et al.*,¹⁸ a mechanism for Mo-catalyzed reductive Cadogan-type reaction of 3-nitro-2-(1-arylvinyl)imidazo[1,2-*a*]pyridines in the presence of PPh₃ to give 3-aryl-1H-pyrroloimidazo[1,2-*a*]pyridines is proposed in Scheme 6.

The reduction of Mo(VI) catalyst **A** will take place in the presence of the PPh₃ leading to the formation of Mo(IV) complex **B**. Then the complexation of 2-nitroimidazopyridine **2** to **B** lead to the formation of complex **C**. Then, the octahedral complex **D** is formed after chelation with the nitro ligand. This complex can evolve toward complex **E** in which the initial nitro group loses an oxygen atom. Complex **E** can then evolve through cleaving of nitrosaromatic ligand **G** yielding to complex **F**. Finally, the leaving of the OPPh₃ ligand from complex **F** recovers the initial catalyst **A** which can restart a new cycle. A second equivalent of PPh₃ attacks the nitrogen atom of **G** leading to complex **H**, which can evolve to oxazaphosphiridine intermediate **I**. Then the nitrogen-phosphore bond in **I** is cleaved leading to the formation of intermediate **J** which thereafter lead to the nitrene derivative **K** accompanied with the formation of OPPh₃. Finally, subsequent cyclization of the resulting intermediate nitrene **K** leads to the formation of pyrroloimidazo[1,2-*a*]pyridine derivative **5**.

Scheme 6. Mo-catalyzed reductive Cadogan-type reaction of 3-nitro-2-(1-arylvinyl)imidazo[1,2-a]pyridines to give 3-aryl-1H-pyrroloimidazo[1,2-a]pyridines

Biological studies.

Screening assay. The analogues generated in this work were initially screened using human colon cancer cell line (HCT116) at 10^{-5} M concentration by CellTiter-Glo® luminescent cell viability assay, which is a homogeneous method of determining the number of viable cells in culture based on quantitation of the ATP present (an indicator of metabolically active cells). The amount of ATP is directly proportional to the number of cells present in culture. The compounds inhibited HCT116 cell proliferation with varying ability as shown in Figure 2. Compounds which were not active on the cell proliferation were excluded from the Figure 2. Of the compounds evaluated, 4 compounds (**3e**, **3g**, **3k**, and **5cc**) showed more than 50% inhibition of HCT116 cell proliferation at 10^{-5} M concentration (Figure 2).

Figure 2. Screening of generated analogues in HCT116 cells. The inhibition of cell proliferation was plotted for each of the analogue at 10^{-5} M concentration in HCT116 cells. Three sets of experiments were carried out. Error bars represent standard deviation.

To find out the most active compound against human colon cancer cell line, the IC_{50} (half-maximal inhibitory concentration) of these active compounds was determined in HCT116 cells in comparison with natural combretastatin A-4 (CA-4).

The analysis of these results show that the replacement of the methoxy group on the phenyl ring by a fluorine atom led to an increase of the antiproliferative activity (compounds **3e** vs **3k**). Among tested compounds (Table 2), the best antiproliferative activity was obtained with compound **5cc** ($IC_{50} = 0.8 \mu M$) having a phenanthren-3-yl group instead of the cycle A of CA-4, and pyrroloimidazo[1,2-*a*]pyridine ring in lieu of cycle B. As compound **5cc** did not have a *Z* double-bond in its skeleton, it should escape to the risk of isomerization which is the Achilles tendon of natural CA-4. This study opens the door to the development of a new structure-activity relationship around this compound to allow the discovery of a new lead-compound.

Table 2. Cytotoxic activity of selected derivatives against HCT116 cells^a

Compound no.	structure	IC ₅₀ (μM) ^b
3e		13.7 ± 1.4
3g		2.2 ± 1.3
3k		2.1 ± 0.2
5cc		0.8 ± 0.002
CA-4		0.01 ± 0.001 ^c

^a HCT-116 human colon carcinoma cells. ^b Compound concentration required to decrease cell growth by 50%; values represent the average SD of three experiments. ^c The IC_{50} value for CA-4 was determined in this study.

Conclusion

In summary, this work reports a Pd-catalyzed cross-coupling reaction between NTH and 2-chloroimidazo[1,2-*a*]pyridines partners leading to the formation of nitro-2-(1-phenylvinyl)imidazopyridine derivatives, subsequent optimization of Codagan-reductive

cyclization allowed the formation of 3-phenyl-1*H*-pyrrolo-imidazo[1,2-*a*]pyridine derivatives which represents a new scaffold in medicinal chemistry. This methodology is suitable for diversity-oriented synthesis technology given the fact that starting from the same building block, diversity can be obtained easily by application of late-stage modification process. Among evaluated derivatives, compound **5cc** exhibited the highest cytotoxic activity ($IC_{50} = 0.8 \mu M$) against human colon cancer cell line.

EXPERIMENTAL SECTION

General Methods. Solvent peaks were used as reference values, with $CDCl_3$ at 7.26 ppm for 1H NMR and 77.16 ppm for ^{13}C NMR. Chemical shifts δ are given in ppm, and the following abbreviations are used: singlet (s), doublet (d), doublet of doublet (dd), triplet (t), multiplet (m) and broad singlet (bs). Reaction courses and product mixtures were routinely monitored by TLC on silica gel, and compounds were visualized with under a UVP Mineralight UVGL-58 lamp (254 nm) and with phosphomolybdic acid/ Δ , anisaldehyde/ Δ , or vanillin/ Δ . Flash chromatography was performed using silica gel 60 (40–63 μm , 230–400 mesh) at medium pressure (200 mbar). Dioxane, dichloromethane, cyclohexane and tetrahydrofuran were dried using the procedures described in D. Perrin Purification of Laboratory Chemicals.¹⁹ Organic extracts were, in general, dried over $MgSO_4$ or Na_2SO_4 . High-resolution mass spectra were recorded with the aid of a MicrOTOF-Q II. All products reported showed 1H and ^{13}C NMR spectra in agreement with the assigned structures.

Microwave Irradiation Experiments.

The Microwave reactor used was a Biotage microwave reaction Kit, 2-5 mL; manufacturer number: 351521. All reactions were conducted in a sealed reaction vessel, and the reaction temperature was monitored by external surface sensor.

General procedure for preparation of hydrazone²⁰

p-toluenesulphonylhydrazide (930 mg, 5 mmol) was placed in a round-bottom boiling flask equipped with reflux condenser in a 10 mL of dry methanol, the ketone (5 mmol) was added slowly and the mixture was heated in an oil bath, at 60 °C. Within 5-60 min the *N*-tosylhydrazone began to precipitate. The mixture was cooled to 0 °C and the product was collected on a Büchner funnel, washed by petroleum ether than was dried *in vacuo* to afford the pure product.

4-Methyl-N'-(1-phenylethylidene)benzenesulfonohydrazide (1a).²¹ white solid (1.34 g, 95% yield); mp 148-151 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.11 (s, 1H), 7.94 (d, *J* = 8.3 Hz, 2H), 7.64 (dd, *J*₁ = 6.6 Hz, *J*₂ = 2.9 Hz, 2H), 7.35-7.30 (m, 5H), 2.41 (s, 3H), 2.17 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 152.8, 144.2, 137.4, 135.6, 129.7 (2CH), 129.6, 128.4 (2CH), 128.2 (2CH), 126.4 (2CH), 21.7 (CH₃), 13.6 (CH₃).

4-Methyl-N'-(1-(naphthalen-2-yl)ethylidene)benzenesulfonohydrazide (1b).²² white solid (1.52 g, 90% yield); mp 260-268 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.18 (s, 1H), 8.02-7.94 (m, 4H), 7.86-7.79 (m, 3H), 7.52-7.49 (m, 2H), 7.35 (d, *J* = 8.0 Hz, 2H), 2.42 (s, 3H), 2.30 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 152.4, 144.2, 135.5, 134.7, 133.8, 132.9, 129.6 (2CH), 128.5, 128.2 (2CH), 128.0, 127.6, 126.9, 126.4, 126.2, 123.5, 21.6, 13.3.

4-Methyl-N'-(1-(phenanthren-3-yl)ethylidene)benzenesulfonohydrazide (1c). white solid (1.9 g, 98%); mp 150-160 °C; IR (film, cm⁻¹): 3214, 1402, 1335, 1305, 1166, 1060, 915, 863, 842, 814, 752, 734, 706, 693, 662; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.89 (s, 1H), 8.67 (d, *J* = 8.1 Hz, 1H), 8.04 (d, *J* = 8.1 Hz, 2H), 7.99-7.82 (m, 4H), 7.79-7.63 (m, 4H), 7.38 (d, *J* = 8.3 Hz, 2H), 2.44 (s, 3H), 2.37 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 152.7, 144.2, 135.5, 135.2, 132.7, 132.2, 130.4, 129.8, 129.6 (2CH), 128.7, 128.6, 128.3 (2CH), 128.0, 126.8, 126.8, 126.4, 124.3, 122.5, 120.8, 21.6, 13.6; HRMS (ESI): for C₂₃H₂₁N₂O₂S (M + H)⁺: *m/z* calcd. 389.1324, found 389.1317.

*N'-(1-(4-Methoxyphenyl)ethylidene)-4-methylbenzenesulfonohydrazide (1d).*²¹ white solid (1.52 g, 96%); mp 168-170 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.92 (d, *J* = 8.0 Hz, 2H), 7.74 (s, 1H), 7.60 (d, *J* = 8.6 Hz, 2H), 7.31 (d, *J* = 7.9 Hz, 2H), 6.85 (d, *J* = 8.6 Hz, 2H), 3.81 (s, 3H), 2.41 (s, 3H), 2.12 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 161.0, 152.8, 144.2, 135.7, 130.0, 129.3 (2CH), 128.3 (2CH), 127.9 (2CH), 113.8 (2CH), 55.4 (OCH₃), 21.7 (CH₃), 13.4 (CH₃).

4-Methyl-N'-(1-(3,4,5-trimethoxyphenyl)ethylidene)benzenesulfonohydrazide (1e).^{5a} white solid (1.77 g, 94%); mp 167-168 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.92 (d, *J* = 8.2 Hz, 2H), 7.76 (s, 1H), 7.30 (d, *J* = 8.2 Hz, 2H), 6.86 (s, 2H), 3.86 (s, 6H), 3.85 (s, 3H), 2.41 (s, 3H), 2.14 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 153.1, 152.5, 144.4, 135.6, 132.9, 129.6 (2CH), 128.4 (2CH), 106.1, 104.1 (2CH), 103.7, 61.0 (OCH₃), 56.3 (2OCH₃), 21.7 (CH₃), 13.6 (CH₃).

4-Methyl-N'-(1-(2,3,4-trimethoxyphenyl)ethylidene)benzenesulfonohydrazide (1f). white solid (1.74 g, 92%); mp 163-165 °C; IR (film, cm⁻¹): 1597, 1494, 1465, 1414, 1340, 1306, 1291, 1217, 1168, 1094, 667; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.84 (d, *J* = 8.3 Hz, 2H), 7.67 (s, 1H), 7.33 (d, *J* = 7.8 Hz, 2H), 6.75-6.64 (m, 2H), 3.88 (s, 6H), 3.56 (s, 3H), 2.45 (s, 3H), 2.18 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 155.0, 152.7, 143.7, 135.8, 129.4 (2CH), 127.9 (2CH), 124.0, 122.2, 120.2, 108.5, 107.2, 61.3, 61.1, 56.2, 25.0, 21.6; HRMS (ESI): for C₁₈H₂₃N₂O₅S (M + H)⁺: *m/z* calcd. 379.1328, found 379.1324

N'-(1-(3,5-Dimethoxyphenyl)ethylidene)-4-methylbenzenesulfonohydrazide (1g).^{12a} white solid (1.7 g, 90%); mp 230-232 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.95 (s, 1H), 7.92 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 8.0 Hz, 2H), 6.78 (d, *J* = 2.1 Hz, 2H), 6.52-6.32 (m, 1H), 3.78 (s, 6H), 2.40 (s, 3H), 2.11 (s, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 160.7 (2C), 152.5, 144.3, 139.4, 135.6, 129.7 (2CH), 128.3 (2CH), 128.0, 104.8 (2CH), 101.8, 55.5 (OCH₃), 21.7 (CH₃), 13.7 (CH₃).

*N'-(1-(3,4-Dimethoxyphenyl)ethylidene)-4-methylbenzenesulfonohydrazide (1h).*²¹ white solid (1.75 g, 93%); mp 220-222 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.94 (d, *J* = 8.1 Hz, 2H), 7.67 (s, 1H), 7.38-7.25 (m, 3H), 7.15 (ddd, *J*₁ = 8.4 Hz, *J*₂ = 2.1 Hz, *J*₃ = 0.8 Hz, 1H), 6.82 (d, *J* = 8.4 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 2.43 (s, 3H), 2.15 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 152.6, 150.6, 148.8, 144.1, 135.5, 130.1, 129.5 (2CH), 128.2 (2CH), 119.6, 110.3, 108.9, 55.9, 55.8, 21.6, 13.2.

*4-Methyl-N'-(1-(p-tolyl)ethylidene)benzenesulfonohydrazide (1i).*²¹ white solid (1.36 g, 90%); mp 195-198 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.93 (d, *J* = 8.0 Hz, 2H), 7.87 (s, 1H), 7.54 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 8.1 Hz, 2H), 7.14 (d, *J* = 8.0 Hz, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 2.14 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 152.8 (C), 144.2 (C), 139.8 (C), 135.7 (C), 134.7 (C), 129.7 (CH), 129.1 (CH), 128.3 (CH), 126.3 (CH), 21.7 (CH₃), 21.4 (CH₃), 13.5 (CH₃).

*N'-(1-(4-Fluorophenyl)ethylidene)-4-methylbenzenesulfonohydrazide (1j).*²¹ white solid (1.36 g, 89%); mp 185-188 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.94 (d, *J* = 8.0 Hz, 2H), 7.79 (s, 1H), 7.65 (dd, *J*₁ = 8.6 Hz, *J*₂ = 5.4 Hz, 2H), 7.35 (d, *J* = 8.0 Hz, 2H), 7.04 (t, *J* = 8.5 Hz, 2H), 2.44 (s, 3H), 2.16 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 163.8 (d, *J*_{C-F} = 250.0 Hz), 151.7 (C), 144.4 (C), 135.6 (C), 133.6 (d, *J*_{C-F} = 2.4 Hz), 129.8 (2CH), 128.4 (CH), 128.3 (3CH), 115.6, 115.3, 21.7 (CH₃), 13.5 (CH₃).

4-Methyl-N'-(1-(3,4,5-trimethoxyphenyl)ethylidene)benzenesulfonohydrazide (1k).^{2b} white solid (1.45 g, 85%); mp 188-190 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.92 (d, *J* = 8.2 Hz, 2H), 7.74 (s, 1H), 7.31 (d, *J* = 8.1 Hz, 2H), 6.86 (s, 2H), 3.86 (s, 6H), 3.85 (s, 3H), 2.41 (s, 3H), 2.14 (s, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm) 152.9 (2C), 152.5 (C), 144.2 (C), 139.6 (C), 135.4 (C), 132.8 (C), 129.5 (2CH), 128.2 (2CH), 103.8 (2CH), 60.9 (CH₃), 56.1 (2CH₃), 21.6 (CH₃), 13.6 (CH₃). HRMS (ESI) (M + H)⁺ *m/z* calcd for C₁₈H₂₃N₂O₅S 379.1322 found 379.1325.

N'-(1-(4-chlorophenyl)ethylidene)-4-methylbenzenesulfonohydrazide (1l).²¹ white solid (1.58 g, 98%); mp 155-156 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.01 (s, 1H), 7.91 (d, *J* = 8.2 Hz, 2H), 7.57 (d, *J* = 8.5 Hz, 2H), 7.31 (t, *J* = 7.6 Hz, 4H), 2.41 (s, 3H), 2.14 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 151.4 (C), 144.4 (C), 135.9 (C), 135.8 (C), 135.5 (C), 129.8 (2CH), 128.7 (2CH), 128.2 (2CH), 127.7 (2CH), 21.7 (CH₃), 13.4 (CH₃).

N'-(1-(4-cyanophenyl)ethylidene)-4-methylbenzenesulfonohydrazide (1m).²¹ white solid (1.34 g, 86%); mp 221-223 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.10 (s, 1H), 7.91 (d, *J* = 8.1 Hz, 2H), 7.74 (d, *J* = 8.3 Hz, 2H), 7.62 (d, *J* = 8.4 Hz, 2H), 7.34 (d, *J* = 8.1 Hz, 2H), 2.42 (s, 3H), 2.17 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 149.9 (C), 144.7 (C), 141.5 (C), 135.3 (C), 132.3 (2CH), 129.9 (2CH), 128.2 (2CH), 126.9 (2CH), 118.6 (C), 113.1 (C), 21.8 (CH₃), 13.3 (CH₃).

N'-(1-([1,1'-biphenyl]-4-yl)ethylidene)-4-methylbenzenesulfonohydrazide (1n).²³ white solid (1.63 g, 90%); mp 194-196 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.54 (s, 1H), 7.85 (d, *J* = 8.0 Hz, 2H), 7.74-7.66 (m, 6H), 7.53-7.30 (m, 5H), 2.37 (s, 3H), 2.22 (s, 3H); ¹³C{¹H} NMR (75 MHz, DMSO-*d*₆) δ 152.6, 143.3, 140.9, 139.3, 136.4, 136.3, 129.4 (2CH), 128.9 (2CH), 127.7, 127.5 (2CH), 126.5 (6CH), 21.0, 14.2.

4-Methyl-N'-(1-(pyridin-3-yl)ethylidene)benzenesulfonohydrazide (1o).²⁴ white solid (1.33 g, 92%); mp 198-200 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.86 (d, *J* = 2.3 Hz, 1H), 8.59 (dd, *J*₁ = 4.8 Hz, *J*₂ = 1.5 Hz, 1H), 8.32 (s, 1H), 8.01-7.88 (m, 3H), 7.41-7.28 (m, 3H), 2.43 (s, 3H), 2.21 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 150.2, 149.7, 147.5, 144.4, 135.2, 133.6, 133.0, 129.7 (2CH), 128.1 (2CH), 123.2, 21.6, 13.2.

4-Methyl-N'-(1-(9-methyl-9H-carbazol-3-yl)ethylidene)-benzenesulfonohydrazide (1p).^{2c} White solid (2.95 mmol, 59%); mp: 177–178°C; ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.32 (d, *J* = 1.2 Hz, 1H), 8.10 (d, *J* = 7.7 Hz, 1H), 8.03 (d, *J* = 8.3 Hz, 2H), 7.89 (dd, *J*₁ = 7.6 Hz, *J*₂ = 1.2 Hz, 2H), 7.51 (t, *J* = 7.6 Hz, 1H), 7.42 (s, 1H), 7.40-7.30 (m, 4H), 7.27 (d, *J* = 7.7 Hz, 1H),

3.83 (s, 3H), 2.43 (s, 3H), 2.31 (s, 3H); $^{13}\text{C}\{1\text{H}\}$ NMR (75MHz, CDCl_3) δ 154.1, 144.2, 141.9, 141.6, 135.8, 129.7 (2CH), 128.5, 128.4 (2CH), 126.2, 124.4, 123.0, 122.6, 120.4, 119.5, 118.8, 108.9, 108.4, 29.3, 21.7, 13.9.

*(E)-N'-(3,4-dihydronaphthalen-1(2H)-ylidene)-4-methylbenzenesulfonohydrazide (1q).*²¹ white solid (1.38 g, 88%); mp 178-180 °C; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 8.05-7.93 (m, 3H), 7.83 (s, 1H), 7.34 (d, $J = 8.1$ Hz, 2H), 7.29-7.16 (m, 2H), 7.10 (dd, $J_1 = 7.3$, $J_2 = 1.7$ Hz, 1H), 2.76-2.69 (m, 2H), 2.49 (t, $J = 6.5$ Hz, 2H), 2.43 (s, 3H), 1.90 (p, $J = 6.5$ Hz, 2H); $^{13}\text{C}\{1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 152.4, 144.1, 139.7, 135.5, 131.6, 129.6 (2CH), 129.5, 128.3, 128.1 (2CH), 126.4, 125.0, 29.3, 25.4, 21.6, 21.4.

(E)-4-methyl-N'-(thiochroman-4-ylidene)benzenesulfonohydrazide (1r). white solid (1.48 g, 89%); mp 199-201 °C; IR (film, cm^{-1}): 3207, 1403, 1343, 1316, 1167, 1089, 998, 917, 761, 707, 681, 664; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 8.08 (s, 1H), 8.01 (dd, $J_1 = 7.9$, $J_2 = 1.2$ Hz, 1H), 7.94 (d, $J = 8.1$ Hz, 2H), 7.34 (d, $J = 8.1$ Hz, 2H), 7.20 (d, $J = 4.2$ Hz, 2H), 7.12 (dt, $J_1 = 8.3$, $J_2 = 4.3$ Hz, 1H), 3.01 – 2.91 (m, 2H), 2.86 (dd, $J_1 = 7.1$, $J_2 = 5.3$ Hz, 2H), 2.43 (s, 3H); $^{13}\text{C}\{1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 150.1, 144.3, 136.2, 135.28, 130.8, 129.7 (2CH), 129.4, 128.2, 128.1 (2CH), 126.9, 125.6, 27.9, 25.7, 21.6; HRMS (ESI): for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_2\text{S}_2$ ($\text{M} + \text{H}^+$): m/z calcd. 333.0731, found 333.0729.

*(E)-N'-(chroman-4-ylidene)-4-methylbenzenesulfonohydrazide (1s).*²¹ white solid (1.36 g, 86%); mp 178-180°C; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 8.17 (s, 1H), 7.98-7.88 (m, 3H), 7.35 (d, $J = 8.0$ Hz, 2H), 7.25 (ddd, $J_1 = 8.9$ Hz, $J_2 = 7.1$ Hz, $J_3 = 1.8$ Hz, 1H), 6.97-6.92 (m, 1H), 6.86 (dd, $J_1 = 8.3$, $J_2 = 1.1$ Hz, 1H), 4.22 (t, $J = 6.2$ Hz, 2H), 2.72 (t, $J = 6.2$ Hz, 2H), 2.44 (s, 3H); $^{13}\text{C}\{1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 157.2, 148.0, 144.3, 135.3, 131.5, 129.6 (2CH), 128.1 (2CH), 125.0, 121.5, 119.7, 117.5, 64.5, 25.2, 21.6.

General procedure for the synthesis of chloroimidazo[1,2-*a*]pyridine derivatives.²⁵

In a 100 mL round bottom flask containing a solution of chloroacetic acid (3.67 g, 38.8 mmol) in water (6 mL), triethylamine (6.12 mL, 44 mmol) was added dropwise. After stirring for a few minutes, 2-aminopyridine or 2-amino-5-bromopyridine (46 mmol) was added and the mixture was heated to reflux in an oil bath for 5 h. The reaction mixture was allowed to cool, ethanol (10 mL) was added, stirred at 5 °C for 2 h to obtain precipitates. These precipitates were collected and dissolved in toluene (25 mL) followed by addition of phosphorous oxychloride (9.7 mL, 104 mmol) at reflux. After 16 h reaction mixture was cooled to room temperature, diluted with cold water (100 mL) and stirred for 15 min. Aqueous layer was separated and neutralized with 10% aqueous NaOH (aq) and the precipitates obtained were filtered and dissolved in dichloromethane. The organic layer was washed with brine, dried over anhydrous MgSO₄ and concentrated under vacuum to afford a brown powder which was purified using column chromatography on silica gel using cyclohexane: ethyl acetate (90:10) as eluent to yield the corresponding chloroimidazo[1,2-*a*]pyridine derivatives.

The isolated chloroimidazo[1,2-*a*]pyridine derivatives in the last step (40 mmol) was added to concentrated sulfuric acid solution (60 mL) under ice bath at 5 °C followed by addition of nitric acid (6 mL) dropwise. After addition, reaction was allowed to stir at room temperature for 3 h. The reaction mixture was poured onto crushed ice, and precipitates were filtered by vacuum filtration and dissolved in dichloromethane. This organic layer was dried on anhydrous sodium sulphate and concentrated under vacuum to yield crude product which was purified by column chromatography on silica gel using cyclohexane: ethyl acetate (8:2) as eluent to give **2a** or **2b**.

*2-Chloro-3-nitroimidazo[1,2-*a*]pyridine (2a)*.²⁵ Yellow solid (6.4 g, 70%); mp 171-173 °C; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.42 (d, *J* = 7.0 Hz, 1H), 7.72 (dt, *J*₁ = 15.8 Hz, *J*₂ = 8.9 Hz, 2H), 7.33 (t, *J* = 6.9 Hz, 1H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 143.5, 140.2, 131.6, 128.6, 128.0, 117.9, 117.1.9

6-Bromo-2-chloro-3-nitroimidazo[1,2-a]pyridine (2b). Yellow solid (7.1 g, 65%); mp 168-170 °C; IR (film, cm⁻¹): 3140, 1507, 1470, 1440, 1414, 1358, 1341, 1318, 1221, 1208, 814; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.58 (s, 1H), 7.79-7.78 (m, 1H), 7.65 (d, *J* = 9.4 Hz, 1H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 141.8, 135.0, 128.0, 122.1, 121.7, 118.4, 112.4; HRMS (ESI): for C₇H₄BrClN₃O₂ (M + H)⁺: *m/z* calcd. 275.9175, found 275.918.

General procedure for the synthesis of substituted chloroimidazo[1,2-a]pyridine derivatives

A 10 mL sealed tube under argon atmosphere was charged with 6-bromo-2-chloro-3-nitroimidazo[1,2-a]pyridine (1.0 mmol, 1.0 equiv.), corresponding boronic acid (1.2 mmol, 1.2 equiv.), Pd(PPh₃)₄ (5 mol %), and K₂CO₃ (3.0 equiv.). Then THF/H₂O (3/1 V/V) was added via syringe, and the mixture was placed into a preheated oil bath at 80 °C and stirred at for 3 hours. After cooling to r.t., DCM was added to the mixture, extracted and dried over MgSO₄. The combined organic layers were evaporated under reduced pressure, and the crude residue was purified by column chromatography on silica gel using cyclohexane and ethyl acetate as eluent (8:2 to 2:8) to afford the corresponding starting material.

2-Chloro-3-nitro-6-phenylimidazo[1,2-a]pyridine (2c). Yellow solid (246 mg, 90%); mp 160-165 °C; IR (film, cm⁻¹): 1517, 1499, 1476, 1452, 1440, 1415, 1344, 1322, 1213, 823, 766, 747, 698; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.60 (s, 1H), 7.93 (d, *J* = 9.2 Hz, 1H), 7.82 (d, *J* = 9.2 Hz, 1H), 7.61 (d, *J* = 7.2 Hz, 2H), 7.56 – 7.48 (m, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 142.6, 140.3, 135.7, 132.0, 129.6 (2CH), 129.3, 127.4 (2CH), 125.3, 124.6, 123.0, 117.7; HRMS (ESI): for C₁₃H₉ClN₃O₂ (M + H)⁺: *m/z* calcd. 274.0383, found 274.0377.

2-Chloro-6-(4-methoxyphenyl)-3-nitroimidazo[1,2-a]pyridine (2d). Yellow solid (279 mg, 92%); mp. 170-175 °C; IR (film, cm⁻¹): 1485, 1472, 1424, 1406, 1342, 1319, 1283, 1248, 1209, 1179, 823, 812; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.54 (s, 1H), 7.89 (d, *J* = 9.2 Hz, 1H), 7.78 (d, *J* = 9.2 Hz, 1H), 7.54 (d, *J* = 8.5 Hz, 2H), 7.04 (d, *J* = 8.6 Hz, 2H), 3.88 (s, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 160.7, 142.5, 140.2, 138.8, 131.8, 131.7, 128.6 (2CH), 127.9,

124.7, 117.6, 115.1 (2CH), 55.6 (OCH₃); HRMS (ESI): for C₁₄H₁₁ClN₃O₃ (M + H)⁺: *m/z* calcd. 304.0489, found 304.048

*2-Chloro-3-nitro-6-(4-(trifluoromethyl)phenyl)imidazo[1,2-*a*]pyridine (2e)*. Yellow solid (324 mg, 95%); mp 172-176 °C; IR (film, cm⁻¹): 1497, 1474, 1409, 1344, 1325, 1214, 824, 814. ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.68 (s, 1H), 7.96-7.76 (m, 6H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 148.3, 137.3, 136.5, 132.2 (d, *J* = 270 Hz), 130.8 (q, *J* = 30 Hz), 125.5, 121.7, 131.5, 127.9 (2CH), 126.7 (q, *J* = 3.5 Hz, 2CH), 125.8 (CH), 118.1 (CH); ¹⁹F{¹H} NMR (188 MHz, CDCl₃) δ -62.8; HRMS (ESI): for C₁₄H₈ClF₃N₃O₂ (M + H)⁺: *m/z* calcd. 342.0257, found 342.0257.

General procedure for the preparation of compounds 3a-s:

A 10 mL sealed tube under argon atmosphere was charged with *N*-tosylhydrazone (1.0 mmol, 1.0 equiv), 2-chloro-3-nitroimidazo[1,2-*a*]pyridine (1.0 mmol, 1.0 equiv.), Pd₂dba₃·CHCl₃ (2.5 mol %), and XPhos (5 mol %). Then dioxane (4.0 mL) was added via syringe, and the mixture was stirred at room temperature for 1 minute before the addition of LiOtBu (2.2 mmol, 2.2 equiv.). Then the tube was put into microwave and stirred at 110 °C for 30 minutes. After cooling to r.t., DCM was added to the mixture. The solvents were evaporated under reduced pressure, and the crude residue was purified by column chromatography on silica gel using cyclohexane and ethyl acetate (7:3 to 3:7) as eluent to afford the desired product.

*3-Nitro-2-(1-phenylvinyl)imidazo[1,2-*a*]pyridine (3a)*. Yellow solid (216 mg, 82% yield); mp 100-102 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm⁻¹): 1481, 1462, 1378, 1363, 1329, 1312, 1208, 1129, 744, 731, 694; ¹H NMR (300 MHz, CDCl₃) δ (ppm). 9.45 (d, *J* = 7.0 Hz, 1H), 7.86 (d, *J* = 8.9 Hz, 1H), 7.68-7.63 (m, 1H), 7.36-7.30 (m, 6H), 6.02 (s, 1H), 5.76 (s, 1H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 150.5, 145.2, 141.9, 138.5, 137.4, 130.7, 128.6 (2CH), 128.3, 127.9, 126.4 (2CH), 120.0, 118.6, 116.7. HRMS (ESI): for C₁₅H₁₂N₃O₂ (M + H)⁺: *m/z* calcd. 266.0930, found 266.0934.

2-(1-(Naphthalen-2-yl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3b). Yellow solid (272 mg, 86% yield); mp 171-172 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1481, 1461, 1382, 1364, 1328, 1312, 1210, 1132, 819, 768, 744, 731; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.45 (d, J = 7.0 Hz, 1H), 7.89 (d, J = 8.9 Hz, 1H), 7.83-7.79 (m, 2H), 7.73-7.66 (m, 3H), 7.63-7.59 (m, 1H), 7.46-7.39 (m, 2H), 7.30-7.25 (m, 1H), 6.15 (s, 1H), 5.84 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 150.6, 145.2, 141.9, 135.9, 133.4, 133.3, 130.8, 128.4 (2CH), 127.9, 127.8, 126.3, 126.2, 125.4, 124.5, 120.4 (CH_2), 118.6, 116.8; HRMS (ESI): for $\text{C}_{19}\text{H}_{14}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}^+$): m/z calcd. 316.1086, found 316.1084.

3-Nitro-2-(1-(phenanthren-3-yl)vinyl)imidazo[1,2-a]pyridine (3c). Yellow solid (328 mg, 90% yield); mp 244-245 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1480, 1463, 1375, 1329, 1312, 1209, 1122, 919, 844, 739, 712; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.47 (d, J = 7.0 Hz, 1H), 8.64 (s, 1H), 8.57-8.54 (m, 1H), 7.92 (d, J = 8.9 Hz, 1H), 7.88-7.84 (m, 2H), 7.72 (s, 2H), 7.69-7.56 (m, 4H), 7.31 (t, J = 7.0 Hz, 1H), 6.20 (s, 1H), 5.92 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 150.6, 142.3, 136.9, 132.4, 132.0, 130.81, 130.5, 130.4, 128.9, 128.8, 128.0, 127.4, 126.8, 126.7, 126.6, 125.7, 125.4, 122.9, 121.0 (CH_2), 120.6, 118.7, 116.8. HRMS (ESI): for $\text{C}_{23}\text{H}_{16}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}^+$): m/z calcd. 366.1243, found 366.1248.

2-(1-(4-Methoxyphenyl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3d). Yellow solid (274 mg, 93% yield); mp 132-133 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 2837, 1510, 1462, 1377, 1364, 1328, 1313, 1253, 1245, 1206, 1179, 1130, 1030, 836, 819, 769, 746; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.43 (d, J = 6.9 Hz, 1H), 7.84 (d, J = 9.0 Hz, 1H), 7.66-7.60 (m, 1H), 7.27-7.25 (m, 3H), 6.82 (d, J = 8.6 Hz, 2H), 5.90 (s, 1H), 5.62 (s, 1H), 3.77 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 159.7, 150.8, 145.2, 141.2, 131.1, 130.7, 127.9, 127.6 (2CH), 118.5, 118.2 (CH_2), 116.7, 114.0 (2CH), 55.4 (OCH_3). HRMS (ESI): for $\text{C}_{16}\text{H}_{14}\text{N}_3\text{O}_3$ ($\text{M} + \text{H}^+$): m/z calcd. 296.1035, found 296.1027.

3-Nitro-2-(1-(3,4,5-trimethoxyphenyl)vinyl)imidazo[1,2-a]pyridine (3e). Yellow solid (287 mg, 81% yield); mp 171-173 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1581, 1525, 1506, 1483, 1380, 1366, 1323, 1242, 1210, 1126; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.40 (d, J = 7.0 Hz, 1H), 7.83 (d, J = 8.9 Hz, 1H), 7.63 (t, J = 8.0 Hz, 1H), 7.26 (t, J = 7.0 Hz, 1H), 6.55 (s, 2H), 5.92 (s, 1H), 5.68 (s, 1H), 3.81 (s, 3H), 3.77 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 153.3 (2C), 150.3, 145.1, 141.7, 138.6, 134.4, 130.8, 127.9, 120.0 (CH_2), 118.6, 116.8, 104.5 (2CH), 61.0 (OCH_3), 56.4 (2OCH_3). HRMS (ESI): for $\text{C}_{18}\text{H}_{18}\text{N}_3\text{O}_5$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 356.1246, found 356.1240.

3-Nitro-2-(1-(2,3,4-trimethoxyphenyl)vinyl)imidazo[1,2-a]pyridine (3f). Yellow solid (321 mg, 90% yield); mp 100-102 °C; R_f = 0.41 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1496, 1482, 1463, 1380, 1364, 1329, 1297, 1209, 1095; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.35 (d, J = 6.9 Hz, 1H), 7.76 (d, J = 8.9 Hz, 1H), 7.58-7.53 (m, 1H), 7.18 (t, J = 6.9 Hz, 1H), 7.05 (d, J = 8.6 Hz, 1H), 6.65 (d, J = 8.7 Hz, 1H), 5.91 (s, 1H), 5.86 (s, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 3.55 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 153.7, 151.7, 151.3, 144.7, 142.2, 138.8, 130.5, 127.7, 126.3, 124.2, 122.9 (CH_2), 118.1, 116.3, 107.5, 60.8 (OCH_3), 60.7 (OCH_3), 55.9 (OCH_3). HRMS (ESI): for $\text{C}_{18}\text{H}_{18}\text{N}_3\text{O}_5$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 356.1246, found 356.1247.

2-(1-(3,5-Dimethoxyphenyl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3g). Yellow solid (305 mg, 94% yield); mp 182-184 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1513, 1482, 1463, 1375, 1328, 1314, 1263, 1210, 1144, 1128, 1024, 769, 746; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.41 (d, J = 6.9 Hz, 1H), 7.83 (d, J = 8.9 Hz, 1H), 7.66-7.60 (m, 1H), 7.26 (t, J = 7.0 Hz, 1H), 6.48 (d, J = 2.1 Hz, 2H), 6.40-6.38 (m, 1H), 6.00 (s, 1H), 5.73 (s, 1H), 3.74 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 160.8 (2C), 150.2, 145.1, 141.7, 140.5, 130.7, 127.8, 120.1 (CH_2), 118.5, 116.7, 105.1 (2CH), 99.9, 55.4 (2OCH_3). HRMS (ESI): for $\text{C}_{17}\text{H}_{16}\text{N}_3\text{O}_4$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 326.1141, found 326.1148.

2-(1-(3,4-Dimethoxyphenyl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3h). Yellow solid (312 mg, 96% yield); mp 177-179 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1513, 1482, 1375, 1329, 1314, 1263, 1245, 1210, 1144, 1128, 1024, 769, 747; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.41 (d, J = 6.9 Hz, 1H), 7.83 (d, J = 8.9 Hz, 1H), 7.63 (t, J = 7.9 Hz, 1H), 7.26 (t, J = 6.9 Hz, 1H), 6.98 (s, 1H), 6.80-6.73 (m, 2H), 5.91 (s, 1H), 5.64 (s, 1H), 3.84 (s, 3H), 3.83 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 150.5, 149.4, 149.0, 145.0, 141.3, 131.4, 130.7, 127.8, 119.2, 118.5, 118.4 (CH_2), 116.6, 1101.0, 109.8, 56.1 (OCH_3), 55.9 (OCH_3). HRMS (ESI): for $\text{C}_{17}\text{H}_{16}\text{N}_3\text{O}_4$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 326.1141, found 326.1142.

3-Nitro-2-(1-(p-tolyl)vinyl)imidazo[1,2-a]pyridine (3i). yellow solid (252 mg, 90% yield); mp 129-131 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1480, 1463, 1376, 1362, 1328, 1312, 1209, 1129, 819, 768, 745, 725; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.43 (d, J = 7.0 Hz, 1H), 7.84 (d, J = 8.9 Hz, 1H), 7.64 (t, J = 8.4 Hz, 1H), 7.28-7.22 (m, 3H), 7.11 (d, J = 7.9 Hz, 2H), 5.97 (s, 1H), 5.69 (s, 1H), 2.32 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 150.7, 145.1, 141.7, 138.0 (2C), 135.6, 130.7, 129.2 (2CH), 127.8, 126.2 (2CH), 119.1, 118.5, 116.6, 21.3. HRMS (ESI): for $\text{C}_{16}\text{H}_{14}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 280.1086, found 280.1082.

2-(1-(4-Fluorophenyl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3j). Yellow solid (237 mg, 84% yield); mp 152-153 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1508, 1482, 1378, 1329, 1314, 1212, 1160, 1130, 842, 820, 771, 746; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.43 (d, J = 6.8 Hz, 1H), 7.85 (d, J = 8.9 Hz, 1H), 7.68-7.62 (m, 1H), 7.34-7.28 (m, 3H), 6.98 (t, J = 8.2 Hz, 2H), 5.95 (s, 1H), 5.73 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 164.4, 162.7 (d, J = 247.5 Hz), 150.2, 145.1, 140.8, 134.6, 130.8, 128.1 (d, J = 8.1, 2CH), 127.8, 119.9, 118.5, 116.8, 115.4 (d, J = 21.7 Hz, 2CH); $^{19}\text{F}\{^1\text{H}\}$ NMR (188 MHz, CDCl_3) δ -113.89; HRMS (ESI): for $\text{C}_{15}\text{H}_{11}\text{N}_3\text{O}_2\text{F}$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 284.0835, found 284.0834.

3-Nitro-2-(1-(3,4,5-trifluorophenyl)vinyl)imidazo[1,2-a]pyridine (3k). yellow solid (299 mg, 94% yield); mp 153-155 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1528,

1483, 1441, 1384, 1370, 1331, 1313, 1208, 1129, 1041, 784, 768, 747; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.44 (d, $J = 7.0$ Hz, 1H), 7.86 (d, $J = 8.9$ Hz, 1H), 7.71 – 7.66 (m, 1H), 7.32 (t, $J = 7.0$ Hz, 1H), 6.98 – 6.93 (m, 2H), 5.97 (s, 1H), 5.82 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 151.3 (ddd, $J = 249.7, 10.1, 4.0$ Hz, 2C), 148.7, 145.2, 139.6 (dt, $J = 252.9, 15.5$, Hz), 139.4, 134.8 (q, $J = 12$ Hz), 131.1, 127.9, 122.0, 118.6, 117.1, 110.7 (d, $J = 21.9$ Hz, 2CH), 110.71 (d, $J = 8.2$ Hz); $^{19}\text{F}\{^1\text{H}\}$ NMR (188 MHz, CDCl_3) δ -134.26 (d, $J = 20.4$ Hz), -160.73 (t, $J = 20.5$ Hz); HRMS (ESI): for $\text{C}_{15}\text{H}_9\text{N}_3\text{O}_2\text{F}_3$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 320.0647, found 320.0645.

2-(1-(4-Chlorophenyl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3l). Yellow solid (219 mg, 73% yield); mp 170-172 °C; $R_f = 0.4$ (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1523, 1479, 1377, 1368, 1328, 1313, 1210, 1128, 1104, 766, 746. ^1H NMR (300 MHz, CDCl_3) δ (ppm): ^1H NMR (300 MHz, CDCl_3 -d) δ 9.38 (d, $J = 6.9$ Hz, 1H), 7.80 (d, $J = 8.9$ Hz, 1H), 7.64-7.58 (m, 1H), 7.18-7.26 (m, 5H), 5.94 (s, 1H), 5.73 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 149.9, 145.1, 140.8 (2C), 137.0, 134.0, 130.9, 128.7 (2CH), 127.8, 127.7 (2CH), 120.5, 118.5, 116.8. HRMS (ESI): for $\text{C}_{15}\text{H}_{11}\text{ClN}_3\text{O}_2$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 300.0540, found 300.0537.

4-(1-(3-Nitroimidazo[1,2-a]pyridin-2-yl)vinyl)benzonitrile (3m). Yellow solid (255 mg, 87% yield); mp 214-216 °C; $R_f = 0.4$ (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1527, 1482, 1380, 1330, 1314, 1212, 1130, 848, 820, 769, 747; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.44 (d, $J = 6.9$ Hz, 1H), 7.87 (d, $J = 8.9$ Hz, 1H), 7.72-7.67 (m, 1H), 7.60 (d, $J = 7.4$ Hz, 2H), 7.45 (d, $J = 8.1$ Hz, 2H), 7.32 (t, $J = 7.0$ Hz, 1H), 6.09 (s, 1H), 5.93 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 149.0, 145.3, 143.0, 140.6, 132.5 (2CH), 131.1, 127.9, 127.1 (2CH), 123.1, 118.8, 118.8, 118.6, 117.1, 111.8; HRMS (ESI): for $\text{C}_{16}\text{H}_{11}\text{N}_4\text{O}_2$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 291.0882, found 291.0887.

2-(1-([1,1'-Biphenyl]-4-yl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3n). Yellow solid (290 mg, 85% yield); mp 209-211 °C; $R_f = 0.4$ (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1483,

1379, 1365, 1330, 1313, 1213, 1129, 764, 741, 698; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.46 (d, $J = 6.8$ Hz, 1H), 7.87 (d, $J = 8.9$ Hz, 1H), 7.68-7.63 (m, 1H), 7.59-7.54 (m, 4H), 7.44-7.39 (m, 4H), 7.34 (d, $J = 7.6$ Hz, 1H), 7.30 (d, $J = 6.9$ Hz, 1H), 6.08 (s, 1H), 5.78 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 150.5, 145.2, 141.4 (2C), 141.1, 140.8, 137.4, 130.8, 128.9 (2CH), 127.9, 127.5, 127.3 (2CH), 127.2 (2CH), 126.8 (2CH), 119.9, 118.6, 116.8; HRMS (ESI): for $\text{C}_{21}\text{H}_{16}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 342.1243, found 342.1248.

3-Nitro-2-(1-(pyridin-3-yl)vinyl)imidazo[1,2-a]pyridine (3o). Yellow solid (213 mg, 80% yield); mp 163-165 °C; $R_f = 0.3$ (cyclohexane/acetone 5/5); IR (film, cm^{-1}): 1633, 1524, 1483, 1380, 1368, 1330, 1313, 1211, 1131, 819, 767, 747, 714; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.38 (d, $J = 6.6$ Hz, 1H), 8.55 (d, $J = 2.0$ Hz, 1H), 8.47 (d, $J = 4.5$ Hz, 1H), 7.81 (d, $J = 8.6$ Hz, 1H), 7.66-7.61 (m, 2H), 7.26 (t, $J = 7.0$ Hz, 1H), 7.22-7.18 (m, 1H), 6.01 (s, 1H), 5.84 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 149.2, 147.6, 145.1, 139.0 (2C), 134.2 (2C), 133.6, 131.0, 127.8, 123.2, 121.9, 118.5, 116.9. HRMS (ESI): for $\text{C}_{14}\text{H}_{11}\text{N}_4\text{O}_2$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 267.0882, found 267.0888.

9-Methyl-3-(1-(3-nitroimidazo[1,2-a]pyridin-2-yl)vinyl)-9H-carbazole (3p). Yellow solid (351 mg, 95% yield); mp 127-129 °C; $R_f = 0.4$ (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1481, 1463, 1379, 1364, 1329, 1314, 1251, 1212, 1128, 768, 747, 730; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.38 (d, $J = 6.9$ Hz, 1H), 8.04 (s, 1H), 7.98 (d, $J = 7.7$ Hz, 1H), 7.85 (d, $J = 8.9$ Hz, 1H), 7.61 – 7.58 (m, 2H), 7.45 – 7.40 (m, 1H), 7.30 – 7.28 (m, 2H), 7.17 (q, $J = 7.6, 7.1$ Hz, 2H), 6.07 (s, 1H), 5.74 (s, 1H), 3.77 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 151.3, 145.1, 142.4, 141.4, 140.9, 130.6, 129.6 (2C), 127.8, 125.8, 124.6, 122.8 (2C), 120.4, 119.0, 118.4, 118.3, 118.1, 116.6, 108.6, 108.4, 29.12 (NCH_3). HRMS (ESI): for $\text{C}_{22}\text{H}_{17}\text{N}_4\text{O}_2$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 369.1352, found 369.1348.

2-(3,4-Dihydronaphthalen-1-yl)-3-nitroimidazo[1,2-a]pyridine (3q). Yellow solid (253 mg, 87% yield); mp 94-96 °C; $R_f = 0.4$ (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1524, 1481,

1439, 1384, 1364, 1332, 1312, 1206, 1134, 764, 735; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.45 (d, $J = 6.9$ Hz, 1H), 7.81 (d, $J = 8.8$ Hz, 1H), 7.63-7.58 (m, 1H), 7.25 (d, $J = 6.8$ Hz, 1H), 7.20 (d, $J = 8.3$ Hz, 1H), 7.13 (t, $J = 7.3$ Hz, 1H), 7.02 (t, $J = 7.4$ Hz, 1H), 6.76 (d, $J = 7.6$ Hz, 1H), 6.47 (t, $J = 4.5$ Hz, 1H), 2.94 (t, $J = 8.0$ Hz, 2H), 2.52 (td, $J_1 = 7.9$, $J_2 = 4.9$ Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 149.4, 145.3, 135.5 (2C), 132.9, 132.2 (2C), 130.6, 127.9, 127.8, 127.5, 126.4, 123.4, 118.3, 116.5, 27.7, 23.5; HRMS (ESI): for $\text{C}_{17}\text{H}_{14}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 292.1086, found 292.1083.

3-Nitro-2-(2H-thiochromen-4-yl)imidazo[1,2-a]pyridine (3r). Yellow solid (257 mg, 83% yield); mp 203-205 $^\circ\text{C}$; $R_f = 0.35$ (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1628, 1525, 1484, 1438, 1382, 1367, 1335, 1314, 1270, 1212, 1127, 765, 733; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.46 (d, $J = 7.0$ Hz, 1H), 7.83 (d, $J = 8.9$ Hz, 1H), 7.68-7.63 (m, 1H), 7.37 (d, $J = 7.7$ Hz, 1H), 7.29 (t, $J = 7.3$ Hz, 1H), 7.12 (t, $J = 7.5$ Hz, 1H), 6.96 (t, $J = 7.5$ Hz, 1H), 6.80 (d, $J = 7.7$ Hz, 1H), 6.42 (t, $J = 5.6$ Hz, 1H), 3.56 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 149.2, 145.2, 133.7 (2C), 132.9, 132.4, 130.8, 128.3, 127.9 (2CH), 126.5, 125.8, 125.5, 118.5, 116.8, 25.2 (SCH_2). HRMS (ESI): for $\text{C}_{16}\text{H}_{12}\text{N}_3\text{O}_2\text{S}$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 310.0650, found 310.0646.

2-(2H-Chromen-4-yl)-3-nitroimidazo[1,2-a]pyridine (3s). Yellow solid (249 mg, 85% yield); mp 187-189 $^\circ\text{C}$; $R_f = 0.35$ (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1527, 1483, 1441, 1387, 1367, 1334, 1314, 1220, 1204, 1133, 1123, 822, 763, 747; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.49 (d, $J = 7.0$ Hz, 1H), 7.85 (d, $J = 8.9$ Hz, 1H), 7.70-7.64 (m, 1H), 7.31 (t, $J = 7.0$ Hz, 1H), 7.17-7.12 (m, 1H), 6.90 (d, $J = 8.3$ Hz, 1H), 6.78 (d, $J = 4.2$ Hz, 2H), 6.19 (t, $J = 3.8$ Hz, 1H), 5.00 (d, $J = 3.8$ Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 154.0, 146.8, 145.4, 133.3, 130.9, 129.8, 129.3 (2C), 128.0, 125.5, 124.4, 121.5, 118.6, 116.9, 116.6, 65.3 (OCH_2). HRMS (ESI): for $\text{C}_{16}\text{H}_{12}\text{N}_3\text{O}_3$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 294.0879, found 294.0874.

2-(2,2-Bis(4-methoxyphenyl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3t). Yellow solid (273 mg, 68% yield); mp 153-155 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1606, 1512, 1483, 1382, 1366, 1330, 1314, 1248, 1213, 1177, 1031, 766, 746; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.48 (d, J = 7.0 Hz, 1H), 7.86 (d, J = 9.3 Hz, 1H), 7.67 (ddd, J = 8.9, 7.1, 1.3 Hz, 1H), 7.35-7.25 (m, 3H), 7.18 (s, 1H), 6.98 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 6.67 (d, J = 8.7 Hz, 2H), 3.82 (s, 3H), 3.74 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 159.3, 158.9, 150.0, 145.8, 145.4, 134.1, 132.8, 131.5, 131.3, 131.0, 130.9, 130.4, 129.9, 129.3, 128.0, 118.5, 116.4, 116.2, 113.9, 113.7, 113.5, 55.29, 55.13. HRMS (ESI): for $\text{C}_{23}\text{H}_{20}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 402.1454, found 402.1457.

2-(1-(4-Methoxyphenyl)vinyl)-3-nitro-6-(4-(trifluoromethyl)phenyl)imidazo[1,2-a] pyridine (3u). Yellow solid (386 mg, 88% yield); mp 173-175 °C; R_f = 0.35 (cyclohexane/ethyl acetate 7/3); IR (film, cm^{-1}): 1512, 1482, 1463, 1322, 1258, 1247, 1211, 1166, 1128, 1112, 1073, 819; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.68 (s, 1H), 8.97-7.87 (m, 2H), 7.82-7.75 (m, 4H), 7.29 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 5.94 (s, 1H), 5.67 (s, 1H), 3.79 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 159.8, 151.4, 144.4, 141.2 (2C), 139.8, 131.2 (q, J = 32 Hz), 131.0, 130.6, 129.9, 127.8 (2CH), 127.7 (2CH), 126.6, 126.5, 125.8, 124.0 (d, J = 270 Hz), 118.7, 118.4, 114.0 (2CH), 55.4; $^{19}\text{F}\{^1\text{H}\}$ NMR (188 MHz, CDCl_3) δ -62.72; HRMS (ESI): for $\text{C}_{23}\text{H}_{17}\text{F}_3\text{N}_3\text{O}_3$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 440.1222, found 440.1219.

6-(4-Methoxyphenyl)-2-(1-(4-methoxyphenyl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3v). Yellow solid (363 mg, 90% yield); R_f = 0.25 (cyclohexane/ethyl acetate 7/3); mp 159-160 °C; IR (film, cm^{-1}): 1608, 1511, 1484, 1464, 1381, 1319, 1257, 1244, 1207, 1180, 1034, 838, 818; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.59 (s, 1H), 7.87 (s, 2H), 7.57 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 5.92 (s, 1H), 5.65 (s, 1H), 3.88 (s, 3H), 3.79 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 160.5, 159.7, 151.0, 144.2, 141.4 (2C), 131.2 (2C), 131.0, 128.6 (2CH), 127.7 (2CH), 124.6, 118.2, 118.1, 115.0 (2CH),

114.0 (2CH), 55.6 (OCH₃), 55.4 (OCH₃). HRMS (ESI): for C₂₃H₂₀N₃O₄ (M + H)⁺: *m/z* calcd. 402.1454, found 402.1447.

2-(1-(4-Methoxyphenyl)vinyl)-3-nitro-6-phenylimidazo[1,2-a]pyridine (3w). Yellow solid (342 mg, 92% yield); mp 147-149 °C; R_f = 0.35 (cyclohexane/ethyl acetate 7/3); IR (film, cm⁻¹): 1607, 1512, 1475, 1381, 1352, 1322, 1247, 1209, 1181, 1032, 834; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.63 (s, 1H), 7.90 (s, 2H), 7.65-7.62 (m, 3H), 7.58-7.39 (m, 4H), 7.30 (d, *J* = 8.7 Hz, 2H), 6.84 (d, *J* = 8.7 Hz, 2H), 5.93 (s, 1H), 5.66 (s, 1H), 3.79 (s, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 159.7, 151.1, 144.3, 141.3 (2C), 136.1, 131.4 (2C), 131.1, 129.5 (2CH), 129.0, 127.6 (2CH), 127.4 (2CH), 125.2, 118.2, 118.1, 114.0 (2CH), 55.3 (OCH₃). HRMS (ESI): for C₂₂H₁₈N₃O₃ (M + H)⁺: *m/z* calcd. 372.1348, found 372.1354.

2,6-Bis(1-(4-methoxyphenyl)vinyl)-3-nitroimidazo[1,2-a]pyridine (3x). Yellow solid (384 mg, 89% yield); mp 150-152 °C; R_f = 0.35 (cyclohexane/ethyl acetate 7/3); IR (film, cm⁻¹): 1606, 1510, 1483, 1460, 1331, 1244, 1207, 1178, 1028, 834, 817, 733; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.43 (s, 1H), 7.77 (d, *J* = 9.2 Hz, 1H), 7.59 (d, *J* = 9.2 Hz, 1H), 7.29 (d, *J* = 2.6 Hz, 2H), 7.26 (d, *J* = 2.6 Hz, 2H), 6.90 (d, *J* = 8.6 Hz, 2H), 6.83 (d, *J* = 8.6 Hz, 2H), 5.91 (s, 1H), 5.64 (s, 1H), 5.59 (s, 1H), 5.50 (s, 1H), 3.83 (s, 3H), 3.78 (s, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 160.2, 159.7, 151.0, 145.0 (2C), 144.6, 141.3 (2C), 132.0, 131.9, 131.1, 129.3 (2CH), 127.6 (2CH), 126.4, 118.2, 117.5, 115.8, 114.2 (2CH), 114.0 (2CH), 55.5 (OCH₃), 55.4 (OCH₃). HRMS (ESI): for C₂₅H₂₂N₃O₄ (M + H)⁺: *m/z* calcd. 428.1610, found 428.1599.

2,6-Bis(3,4-dihydronaphthalen-1-yl)-3-nitroimidazo[1,2-a]pyridine (3y). Yellow solid (302 mg, 72% yield); mp 210-211 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm⁻¹): 1525, 1485, 1464, 1418, 1386, 1356, 1320, 1211, 737, 701; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.50 (s, 1H), 7.81 (d, *J* = 9.1 Hz, 1H), 7.76 (dd, *J* = 9.0, 1.7 Hz, 1H), 7.25-7.13 (m, 5H), 7.07 (t, *J* = 7.3 Hz, 1H), 6.94 (d, *J* = 7.6 Hz, 1H), 6.82 (d, *J* = 7.7 Hz, 1H), 6.51 (t, *J* = 4.6 Hz, 1H), 6.28 (t, *J* = 4.6 Hz, 1H), 3.01-2.90 (m, 4H), 2.59-2.48 (m, 4H); ¹³C{¹H} NMR (75 MHz, CDCl₃)

δ (ppm): 157.2, 136.8, 135.8, 135.7, 135.6, 135.5, 133.9, 133.0, 132.8, 132.4, 132.3, 130.9, 130.8, 128.2, 128.1, 127.9, 127.6, 126.8, 126.6, 126.5, 125.0, 123.6, 117.4, 28.0, 27.8, 23.7, 23.6; HRMS (ESI): for $C_{27}H_{22}N_3O_2$ ($M + H$)⁺: m/z calcd. 420.1712, found 420.1707.

2,6-Di(2H-chromen-4-yl)-3-nitroimidazo[1,2-a]pyridine (3z) Yellow solid (326 mg, 77% yield); mp 223-224 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1484, 1420, 1389, 1345, 1321, 1225, 1205, 1065, 733; 1H NMR (300 MHz, $CDCl_3$) δ (ppm): 9.51 (s, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.65-7.62 (m, 1H), 7.25-7.20 (m, 1H), 7.18-7.13 (m, 1H), 6.97-6.87 (m, 4H), 6.82-6.77 (m, 2H), 6.22 (t, J = 3.8 Hz, 1H), 6.00 (t, J = 3.9 Hz, 1H), 5.01 (d, J = 3.8 Hz, 2H), 4.92 (d, J = 3.9 Hz, 2H); $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ (ppm): 157.9, 154.8, 147.1, 132.8, 132.2, 131.3, 131.3, 130.4, 129.9, 129.3, 128.6 (2C), 126.6, 125.6, 125.2, 124.4, 122.9, 122.5 (2C), 121.8, 121.5, 117.9, 116.9, 116.6, 65.3, 65.1; HRMS (ESI): for $C_{25}H_{18}N_3O_4$ ($M + H$)⁺: m/z calcd. 424.1297, found 424.1288.

General procedure for the preparation of compounds 4.²⁶

Iron powder (112 mg, 2 mmol, 10 equiv.) and concd hydrochloric acid (*ca.* 1 μ L) were added to a solution of nitro-compound (0.2 mmol) in EtOH (0.5 mL) and water (120 μ L), and the mixture was heated to reflux in an oil bath for 90 min. DCM (20 mL) was added to the mixture, and it was dried with $MgSO_4$. After filtration and evaporation of the solvent, the residue was purified by chromatography to give the amino product.

2-(1-Phenylvinyl)imidazo[1,2-a]pyridin-3-amine (4a). Yellow solid (43 mg, 92% yield); mp 76-77 °C; R_f = 0.3 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1657, 1637, 1597, 1573, 1523, 1493, 1435, 1349, 1299, 1279, 898, 757, 732; 1H NMR (300 MHz, $CDCl_3$) δ (ppm): 7.83 (d, J = 6.4 Hz, 1H), 7.51 (d, J = 9.1 Hz, 1H), 7.45-7.34 (m, 5H), 7.10 – 7.05 (m, 1H), 6.75 (t, J = 6.7 Hz, 1H), 5.93 (s, 1H), 5.50 (s, 1H), 2.89 (s, 2H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ (ppm):

141.9, 140.3, 140.3, 128.8 (2CH), 128.2, 128.0 (2CH), 125.1, 123.8, 122.2, 122.0, 117.1, 116.5, 112.0; HRMS (ESI): for $C_{15}H_{14}N_3$ ($M + H$) $^+$: m/z calcd. 236.1188, found 236.1189.

2-(1-(Phenanthren-3-yl)vinyl)imidazo[1,2-a]pyridin-3-amine (4b). Yellow solid (61 mg, 91% yield); mp 177-179 °C; R_f = 0.3 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1657, 1636, 1601, 1506, 1453, 1435, 1378, 1350, 1268, 1241, 844, 750, 732; 1H NMR (300 MHz, $CDCl_3$) δ (ppm): 8.76 (s, 1H), 8.64 (d, J = 8.8 Hz, 1H), 7.90 (d, J = 8.1 Hz, 2H), 7.82 (d, J = 6.9 Hz, 1H), 7.68 (s, 2H), 7.65-7.53 (m, 4H), 7.12-7.06 (m, 1H), 6.75 (t, J = 6.7 Hz, 1H), 6.09 (s, 1H), 5.68 (s, 1H), 2.87 (s, 2H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ (ppm): 139.5, 138.1, 137.0, 132.3, 132.0, 130.4, 130.1, 129.1, 128.7, 127.7, 127.2, 127.1, 127.0, 126.9, 126.8, 126.4, 126.2, 123.5, 122.8, 122.0, 118.2, 114.6, 113.6. HRMS (ESI): for $C_{23}H_{18}N_3$ ($M + H$) $^+$: m/z calcd. 336.1501, found 336.1504.

2-(1-(3,4,5-Trimethoxyphenyl)vinyl)imidazo[1,2-a]pyridin-3-amine (4c). Yellow solid (61 mg, 94% yield); mp 123-125 °C; R_f = 0.25 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 2937, 1579, 1504, 1465, 1411, 1323, 1235, 1125, 1005, 733; 1H NMR (300 MHz, $CDCl_3$) δ (ppm): 7.82 (d, J = 6.7 Hz, 1H), 7.49 (d, J = 9.1 Hz, 1H), 7.08-7.03 (m, 1H), 6.74 (t, J = 6.8 Hz, 1H), 6.64 (s, 2H), 5.87 (s, 1H), 5.45 (s, 1H), 3.86 (s, 3H), 3.81 (s, 6H), 3.0 (s, 2H); $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ (ppm): 153.5, 142.2 (2C), 140.5, 138.1, 136.2, 130.1, 125.2, 123.3, 121.8, 117.4, 115.6, 111.8, 105.23 (2CH), 61.0 (OCH_3), 56.3 ($2OCH_3$). HRMS (ESI): for $C_{18}H_{20}N_3O_3$ ($M + H$) $^+$: m/z calcd. 326.1505, found. 326.1503.

2-(1-(3,5-Dimethoxyphenyl)vinyl)imidazo[1,2-a]pyridin-3-amine (4d). Yellow solid (56 mg, 95% yield); mp 145-147 °C; R_f = 0.3 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 2837, 1605, 1587, 1454, 1422, 1316, 1299, 1204, 1154, 1064, 1046, 836, 753, 732; 1H NMR (300 MHz, $CDCl_3$) δ (ppm): 7.82 (d, J = 6.8 Hz, 1H), 7.49 (d, J = 9.1 Hz, 1H), 7.09-7.04 (m, 1H), 6.74 (t, J = 6.7 Hz, 1H), 6.58 (d, J = 2.2 Hz, 2H), 6.47-6.46 (m, 1H), 5.94 (s, 1H), 5.48 (s, 1H), 3.77 (s, 6H), 2.99 (s, 2H). $^{13}C\{^1H\}$ NMR (75 MHz, $CDCl_3$) δ (ppm): 161.2 (2C), 142.1, 141.4, 139.8,

128.0, 125.6, 124.4, 122.4, 116.6, 116.5, 112.3, 106.1 (2CH), 100.4, 55.6 (2OCH₃). HRMS (ESI): for C₁₇H₁₈N₃O₂ (M + H)⁺: *m/z* calcd. 296.1399, found 296.1398.

*2-(1-(3,4,5-Trifluorophenyl)vinyl)imidazo[1,2-*a*]pyridin-3-amine (4e)*. Yellow solid (56 mg, 97% yield); mp 93-95 °C; R_f = 0.35 (cyclohexane/ethyl acetate 5/5); IR (film, cm⁻¹): 1619, 1526, 1435, 1332, 1235, 1041, 862, 781, 740, 697; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.88 (d, *J* = 6.9 Hz, 1H), 7.46 (d, *J* = 9.1 Hz, 1H), 7.10-7.03 (m, 3H), 6.78 (t, *J* = 6.7 Hz, 1H), 5.75 (s, 1H), 5.60 (s, 1H), 3.23 (s, 2H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 151.23 (dd, *J* = 252.0, 11.7 Hz), 139.4 (2C), 138.7, 136.84 (d, *J* = 176.7 Hz), 126.4, 126.0, 125.3, 122.8, 118.2, 116.1, 112.9, 112.0 (d, *J* = 21.6 Hz, 2C), 112.0 (d, *J* = 8.2 Hz); ¹⁹F {¹H} NMR (188 MHz, CDCl₃) δ -133.92 (d, *J* = 20.6 Hz), -160.53 (t, *J* = 20.6 Hz); HRMS (ESI): for C₁₅H₁₁F₃N₃ (M + H)⁺: *m/z* calcd. 290.0905, found 290.0903.

*2-(2H-Thiochromen-4-yl)imidazo[1,2-*a*]pyridin-3-amine (4f)*. Yellow solid (45 mg, 80% yield); mp 153-155 °C; R_f = 0.35 (cyclohexane/ethyl acetate 5/5); IR (film, cm⁻¹): 1640, 1586, 1515, 1467, 1433, 1358, 1331, 1270, 1145, 769, 731; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.03 (d, *J* = 6.9 Hz, 1H), 7.62 (d, *J* = 8.9 Hz, 1H), 7.39 (d, *J* = 7.1 Hz, 1H), 7.21-7.10 (m, 4H), 6.87 (t, *J* = 6.8 Hz, 1H), 6.52 (t, *J* = 5.8 Hz, 1H), 3.49 (d, *J* = 5.9 Hz, 2H), 2.24 (s, 2H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 140.5, 133.9, 133.5, 132.5, 130.4, 128.3, 128.0, 127.2, 125.9, 124.4, 124.1, 123.5, 122.0, 117.2, 112.1, 25.5 (SCH₂). HRMS (ESI): for C₁₆H₁₄N₃S (M + H)⁺: *m/z* calcd. 280.0908, found 280.0910.

*2-(2H-Chromen-4-yl)imidazo[1,2-*a*]pyridin-3-amine (4g)*. Yellow solid (43 mg, 82% yield); mp 157-159 °C; R_f = 0.3 (cyclohexane/ethyl acetate 5/5); IR (film, cm⁻¹): 1639, 1604, 1579, 1523, 1486, 1448, 1376, 1331, 1225, 1066, 756, 733; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.29 (s, 1H), 8.04 (d, *J* = 5.7 Hz, 1H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.21-7.09 (m, 3H), 6.91-6.88 (m, 2H), 6.15 (s, 1H), 5.77 (s, 2H), 4.86 (s, 2H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 154.7 (C), 139.0 (C), 123.0 (CH), 126.9 (C), 126.4 (CH), 125.7 (C), 125.2 (CH), 124.7 (CH), 123.2

(C), 122.9 (CH), 121.8 (CH), 121.6 (C), 116.8 (CH), 115.3 (CH), 113.7 (CH), 65.3 (OCH₃).

HRMS (ESI): for C₁₆H₁₄N₃O (M + H)⁺: *m/z* calcd. 264.1137, found 264.1135.

General procedure for the preparation of compounds **5**.

A 10 mL sealed tube under argon atmosphere was charged with compounds **3** (0.5 mmol, 1.0 equiv.) and PPh₃ (4 equiv.), and MoO₂Cl₂(dmf)₂ (10 mol%). Then dioxane (3.0 mL) was added via syringe. Then the tube was sealed and stirred at 135 °C under microwave irradiation for 4 hours. After cooling to r.t., DMAP (20 mol%), NEt₃ (3.0 equiv.) and (Boc)₂O (0.65 mmol) was added and then the reaction mixture was stirred at r.t. for 2 hours. After completion (TLC), DCM was added to the reaction mixture and the solvents were evaporated under reduced pressure. Then the crude residue was purified by column chromatography on silica gel using cyclohexane and ethyl acetate as eluent to afford the desired product.

Tert-butyl 3-phenyl-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5a). Yellow solid (136 mg, yield 82%); mp 146-147 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm⁻¹): 1727, 1519, 1354, 1288, 1270, 1204, 1155, 1109, 1064, 741; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.25 (d, *J* = 7.5 Hz, 1H), 8.09 (d, *J* = 8.1 Hz, 2H), 7.70 (d, *J* = 9.3 Hz, 1H), 7.57 (s, 1H), 7.46 (t, *J* = 7.6 Hz, 2H), 7.31 (d, *J* = 7.8 Hz, 1H), 7.19-7.14 (m, 1H), 6.78 (t, *J* = 6.9 Hz, 1H), 1.72 (s, 9H). ¹³C{¹H} NMR (95 MHz, CDCl₃) δ (ppm): 148.7, 147.6, 135.8, 132.7 (2C), 128.9 (2CH), 127.2, 126.4 (3CH), 123.7, 118.7, 117.9, 117.7, 110.7, 85.2, 28.3 (3CH₃). HRMS (ESI): for C₂₀H₂₀N₃O₂ (M + H)⁺: *m/z* calcd. 334.1556, found 334.1552.

Tert-butyl 3-(naphthalen-2-yl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5b). Yellow solid (178 mg, yield 93%); mp 172-174 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm⁻¹): 1727, 1520, 1371, 1353, 1338, 1284, 1203, 1154, 1108, 758, 742; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.24 (d, *J* = 5.2 Hz, 1H), 8.69 (s, 1H), 8.09-8.05 (m, 1H), 7.99 (d, *J* = 7.9 Hz, 1H), 7.88 (d, *J* = 8.6 Hz, 1H), 7.82 (d, *J* = 7.5 Hz, 1H), 7.74 (d, *J* = 9.3 Hz, 1H), 7.65 (s, 1H), 7.51-7.41 (m, 2H), 7.20-7.14 (m, 1H), 6.76 (t, *J* = 6.6 Hz, 1H), 1.73 (s, 9H).

$^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 148.6, 147.6, 138.3, 134.0, 132.8, 130.1, 128.4 (2CH), 127.7, 126.2, 125.7, 125.2 (2CH), 124.2, 123.6, 119.0, 117.9, 117.6, 110.6, 85.2, 28.3 (3CH₃); HRMS (ESI): for $\text{C}_{24}\text{H}_{23}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}$): m/z calcd. 384.1712, found 384.1721.

Tert-butyl 3-(phenanthren-3-yl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5c). IR (film, cm^{-1}): 1727, 1519, 1353, 1286, 1203, 1154, 1109, 737. Yellow solid (195 mg, 90% yield); mp 185-187 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.46 (s, 1H), 9.24 (d, J = 3.4 Hz, 1H), 8.93 (d, J = 8.1 Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.88 (d, J = 7.7 Hz, 1H), 7.78-7.70 (m, 5H), 7.60 (t, J = 7.3 Hz, 1H), 7.21-7.16 (m, 1H), 6.77 (t, J = 6.8 Hz, 1H), 1.75 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 148.7, 147.6, 138.5, 132.4 (2C), 131.3 (2C), 131.0, 130.9, 130.5, 129.0, 128.5, 126.8, 126.7 (2CH), 126.7, 126.6, 124.9, 123.6, 123.4, 120.3, 118.9, 118.0, 110.6, 85.2, 28.3 (3CH₃); HRMS (ESI): for $\text{C}_{28}\text{H}_{24}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}$): m/z calcd. 434.1869, found 434.1870.

Tert-butyl 3-(4-methoxyphenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5d). Yellow solid (115 mg, 63% yield); mp 166-168 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1722, 1520, 1508, 1353, 1338, 1256, 1242, 1180, 1154, 1105, 1064, 759, 742; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.24 (s, 1H), 8.02 (d, J = 8.5 Hz, 2H), 7.68 (d, J = 9.1 Hz, 1H), 7.46 (s, 1H), 7.17-7.12 (m, 1H), 6.99 (d, J = 8.5 Hz, 2H), 6.76 (t, J = 6.6 Hz, 1H), 3.85 (s, 3H), 1.70 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ (ppm): 159.0, 148.8, 147.5, 138.3, 127.6 (2CH), 126.2, 125.4 (2C), 123.6, 117.8, 117.7, 117.4, 114.4 (2CH), 110.6, 82.2, 55.5 (OCH_3), 28.3 (3CH₃); HRMS (ESI): for $\text{C}_{21}\text{H}_{22}\text{N}_3\text{O}_3$ ($\text{M} + \text{H}$): m/z calcd. 364.1661, found 364.1665.

Tert-butyl 3-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5e). Yellow solid (165 mg, 78% yield); mp 118-120 °C; R_f = 0.35 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1728, 1584, 1505, 1356, 1327, 1244, 1152, 1126, 1006, 732. ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.23 (d, J = 3.6 Hz, 1H), 7.65 (d, J = 9.3 Hz, 2H), 7.46

(s, 1H), 7.32 (s, 2H), 7.15 (dd, $J = 9.2, 6.8$ Hz, 1H), 6.76 (t, $J = 6.9$ Hz, 1H), 4.00 (s, 6H), 3.89 (s, 3H), 1.71 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ (ppm): 153.7, 148.7, 147.5 (2C), 138.4, 137.8, 128.5 (2C), 128.2 (2C), 126.2, 123.5, 118.3, 118.0, 110.6, 104.1 (2CH), 85.3, 61.1 (OCH₃), 56.5 (2OCH₃), 28.3 (3CH₃); HRMS (ESI): for $\text{C}_{23}\text{H}_{26}\text{N}_3\text{O}_5$ ($\text{M} + \text{H}$): m/z calcd. 424.1872, found 424.1860.

Tert-butyl 3-(2,3,4-trimethoxyphenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5f). Yellow oil (160 mg, 76% yield); mp 130-132 °C; $R_f = 0.4$ (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1723, 1465, 1353, 1200, 1154, 1106, 1089, 1026, 745; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.26 (d, $J = 5.9$ Hz, 1H), 8.37 (d, $J = 8.7$ Hz, 1H), 7.91 (s, 1H), 7.67 (d, $J = 9.3$ Hz, 1H), 7.16-7.11 (m, 1H), 6.84 (d, $J = 8.8$ Hz, 1H), 6.76 (t, $J = 6.8$ Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.90 (s, 3H), 1.70 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 152.8, 151.2, 148.9, 147.2, 142.8, 139.2, 126.2, 124.6, 123.4, 121.5, 119.6 (2C), 117.8, 113.4, 110.6, 108.1, 84.7, 61.0 (OCH₃), 60.1 (OCH₃), 56.2 (OCH₃), 28.2 (3CH₃). HRMS (ESI): for $\text{C}_{23}\text{H}_{26}\text{N}_3\text{O}_5$ ($\text{M} + \text{H}$): m/z calcd. 424.1872, found 424.1869.

Tert-butyl 3-(3,5-dimethoxyphenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5g). Yellow solid (125 mg, 64% yield); mp 178-180 °C; $R_f = 0.3$ (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1725, 1610, 1518, 1355, 1286, 1248, 1203, 1152, 1108, 1065, 1048, 851, 760, 742; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.15 (d, $J = 5.6$ Hz, 1H), 7.59 (d, $J = 9.1$ Hz, 1H), 7.45 (s, 1H), 7.20 (d, $J = 1.7$ Hz, 2H), 7.10-7.05 (m, 1H), 6.68 (t, $J = 6.9$ Hz, 1H), 6.36 (s, 1H), 3.82 (s, 6H), 1.63 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ (ppm): 161.3 (2C), 148.7, 147.5, 138.3, 134.6 (2C), 126.2, 123.5, 119.1, 117.9, 117.8, 110.6, 104.7 (2CH), 99.6, 85.2, 55.6 (2OCH₃), 28.3 (3CH₃). HRMS (ESI): for $\text{C}_{22}\text{H}_{24}\text{N}_3\text{O}_4$ ($\text{M} + \text{H}$): m/z calcd. 394.1767, found 394.1768.

Tert-butyl 3-(3,4-dimethoxyphenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5h). Yellow solid (138 mg, 70% yield); mp 160-164 °C; $R_f = 0.3$

(cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1724, 1517, 1353, 1248, 1155, 1108, 1027, 762, 744; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.24 (s, 1H), 7.70 (t, $J = 9.5$ Hz, 2H), 7.55 (d, $J = 1.3$ Hz, 1H), 7.45 (s, 1H), 7.18-7.13 (m, 1H), 6.96 (d, $J = 8.3$ Hz, 1H), 6.77 (t, $J = 6.7$ Hz, 1H), 4.02 (s, 3H), 3.92 (s, 3H), 1.71 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 149.4, 148.7, 148.6, 147.4, 138.2, 131.4, 126.2, 125.7 (2C), 123.6, 119.4, 117.9, 117.7, 111.8, 110.7, 109.7, 85.1, 56.3 (OCH_3), 56.1 (OCH_3), 28.3 (3CH_3). HRMS (ESI): for $\text{C}_{22}\text{H}_{24}\text{N}_3\text{O}_4$ ($\text{M} + \text{H}$): m/z calcd. 394.1767, found 394.1766.

Tert-butyl 3-(p-tolyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5i). Yellow solid (108 mg, 62% yield); mp 175-177 $^\circ\text{C}$; $R_f = 0.3$ (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1724, 1520, 1371, 1354, 1289, 1272, 1203, 1156, 1106, 759, 742; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.25 (s, 1H), 7.98 (d, $J = 7.8$ Hz, 2H), 7.69 (d, $J = 9.2$ Hz, 2H), 7.52 (s, 1H), 7.25 (d, $J = 7.7$ Hz, 2H), 7.18-7.12 (m, 1H), 6.76 (t, $J = 6.8$ Hz, 1H), 2.38 (s, 3H), 1.70 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 148.7, 147.4, 138.3, 136.9 (2C), 129.8, 129.6 (3CH), 126.1 (2CH), 123.6, 117.8, 117.6, 117.5, 110.6, 85.0, 28.3 (3CH_3), 21.5 (CH_3). HRMS (ESI): for $\text{C}_{21}\text{H}_{20}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}$): m/z calcd. 348.1712, found 348.1707.

Tert-butyl 3-(4-fluorophenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5j). Yellow solid (128 mg, 49% yield); 181-183 $^\circ\text{C}$; $R_f = 0.3$ (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1728, 1519, 1505, 1372, 1354, 1156, 1109, 1061, 838, 759, 742; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.25 (d, $J = 7.3$ Hz, 1H), 8.08-7.04 (m, 2H), 7.70-7.67 (m, 1H), 7.50 (s, 1H), 7.20-7.11 (m, 3H), 6.78 (td, $J_1 = 6.9$, $J_2 = 1.2$ Hz, 1H), 1.71 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 162.2 d, $J = 248$ Hz), 148.6, 147.6, 138.2, 133.5, 128.9, 128.0 (d, $J = 7.8$ Hz, 2CH), 126.3, 123.8, 118.4, 117.9, 116.8, 115.8 (d, $J = 21.6$ Hz, 2CH), 110.7, 85.3, 28.3 (3CH_3); $^{19}\text{F}\{^1\text{H}\}$ NMR (188 MHz, CDCl_3) δ -114.92; HRMS (ESI): for $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_2\text{F}$ ($\text{M} + \text{H}$): m/z calcd. 352.1461, found 352.1466.

Tert-butyl 3-(3,4,5-trifluorophenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5k). Yellow solid (117 mg, 60% yield); 180-182 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1734, 1524, 1433, 1370, 1333, 1287, 1246, 1154, 1109, 1043, 733; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.21 (d, J = 6.3 Hz, 1H), 7.72-7.65 (m, 3H), 7.46 (s, 1H), 7.21-7.16 (m, 1H), 6.79 (t, J = 6.8 Hz, 1H), 1.72 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ (ppm): 151.1 (ddd, J = 249.7, 10.1, 4.0 Hz), 148.4, 147.8, 145.9 (d, J = 12 Hz), 138.7 (dd, J = 253, 15 Hz, 2C), 137.5, 129.0, 126.3, 124.1, 119.1, 117.9, 115.0, 111.0, 110.2 (d, J = 22.0 Hz, 2CH), 85.8, 28.3 (3CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (188 MHz, CDCl_3) δ -134.44 (d, J = 20.5 Hz), -162.54 (t, J = 20.7 Hz); HRMS (ESI): for $\text{C}_{20}\text{H}_{17}\text{F}_3\text{N}_3\text{O}_2$ ($\text{M} + \text{H}$): m/z calcd. 388.1273, found 388.1281.

Tert-butyl 3-(4-chlorophenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5l). Yellow solid (116 mg, 63% yield); mp 179-181 °C; R_f = 0.4 (cyclohexane/ethyl acetate 5/5); IR (film, cm^{-1}): 1724, 1518, 1352, 1337, 1288, 1204, 1153, 1108, 1091, 1060, 834, 759, 741; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.24 (d, J = 6.4 Hz, 1H), 8.03 (d, J = 8.4 Hz, 2H), 7.68 (d, J = 9.1 Hz, 1H), 7.54 (s, 1H), 7.41 (d, J = 8.4 Hz, 2H), 7.20-7.15 (m, 1H), 6.78 (t, J = 6.9 Hz, 1H), 1.71 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (95 MHz, CDCl_3) δ (ppm): 148.6, 147.7, 143.2, 137.9, 132.8, 131.3, 129.1 (2CH), 127.6 (2CH), 126.3, 123.9, 118.7, 117.9, 116.6, 110.8, 85.4, 28.3 (3CH₃). HRMS (ESI): for $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_2\text{Cl}$ ($\text{M} + \text{H}$): m/z calcd. 368.1166, found 368.1166.

Tert-butyl 3-(4-cyanophenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5m). Yellow solid (152 mg, 85% yield); mp 294-296 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1731, 1608, 1518, 1372, 1354, 1291, 1202, 1155, 1110, 1061, 847, 744; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.20 (d, J = 6.6 Hz, 1H), 8.15 (d, J = 8.2 Hz, 2H), 7.69-7.60 (m, 4H), 7.21-7.16 (m, 1H), 6.79 (t, J = 6.9 Hz, 1H), 1.72 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 148.3, 147.8, 137.7, 137.5, 132.6 (2CH), 126.5 (2CH), 126.3, 124.2, 119.9, 119.3 (2C), 117.9, 115.7, 111.0, 110.1, 85.9, 28.3 (3CH₃). HRMS (ESI): for $\text{C}_{21}\text{H}_{19}\text{N}_4\text{O}_2$ ($\text{M} + \text{H}$): m/z calcd. 359.1508, found 359.1512.

Tert-butyl 3-([1,1'-biphenyl]-4-yl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5n). Yellow solid (153 mg, yield 75%); mp 296-299 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1727, 1519, 1395, 1354, 1288, 1202, 1155, 1106, 1065, 847, 756, 743; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.25 (d, J = 6.0 Hz, 1H), 8.17 (d, J = 7.8 Hz, 2H), 7.73-7.60 (m, 6H), 7.45 (t, J = 7.4 Hz, 2H), 7.37-7.32 (m, 1H), 7.19-7.14 (m, 1H), 6.77 (t, J = 6.8 Hz, 1H), 1.73 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 148.6, 147.6, 141.1, 139.9, 138.3, 131.8 (2C), 128.9 (2CH), 127.6 (2CH), 127.3, 127.1 (2CH), 126.7 (2CH), 126.2, 123.6, 118.6, 117.9, 117.3, 110.6, 85.2, 28.3 (3 CH_3). HRMS (ESI): for $\text{C}_{26}\text{H}_{24}\text{N}_3\text{O}_2$ ($\text{M} + \text{H}$): m/z calcd. 410.1869, found 410.1877.

Tert-butyl 3-(pyridin-3-yl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5o). Yellow solid (137 mg, 82% yield); mp 172-174 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1730, 1518, 1372, 1355, 1286, 1205, 1156, 1110, 760; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.24 (d, J = 6.6 Hz, 1H), 9.18 (d, J = 6.6 Hz, 1H), 8.53 (dd, J_1 = 4.9 Hz, J_2 = 1.7 Hz, 1H), 8.49 (dt, J_1 = 7.9 Hz, J_2 = 2.0 Hz, 1H), 7.68 (d, J = 9.3 Hz, 1H), 7.61 (s, 1H), 7.37 (dd, J_1 = 7.9 Hz, J_2 = 4.8 Hz, 1H), 7.21-7.15 (m, 1H), 6.79 (t, J = 6.9 Hz, 1H), 1.72 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 148.5 (C), 148.2 (CH), 147.8 (C), 147.2 (CH), 139.9, 138.2, 133.9 (CH), 128.9 (C), 126.3 (CH), 124.0 (CH), 123.8 (CH), 118.9 (CH), 117.9 (CH), 114.4 (C), 110.8 (CH), 85.6 (C), 28.3 (3 CH_3). HRMS (ESI): for $\text{C}_{19}\text{H}_{16}\text{N}_4\text{O}_2$ ($\text{M} + \text{H}$): m/z calcd. 335.1508, found 335.1502.

Tert-butyl 3-(9-methyl-9H-carbazol-3-yl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5p). Yellow solid (135 mg, 62% yield); mp 198-200 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1726, 1519, 1352, 1336, 1246, 1151, 1107, 746, 726; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.29 (d, J = 5.8 Hz, 1H), 8.79 (s, 1H), 8.29-8.25 (m, 2H), 7.76 (d, J = 9.2 Hz, 1H), 7.63 (s, 1H), 7.47 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.28-7.16 (m, 2H), 6.79 (t, J = 6.9 Hz, 1H), 3.88 (s, 3H), 1.75 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz,

CDCl₃) δ (ppm): 148.9, 147.4, 141.6 (2C), 140.6 (2C), 126.3, 125.9, 124.8, 123.7, 123.6, 123.4, 123.1, 121.0, 119.0, 118.7, 118.1, 117.9, 117.7, 110.7, 108.8, 108.6, 85.0, 29.3 (NCH₃), 28.4 (3CH₃). HRMS (ESI): for C₂₇H₂₅N₃O₂ (M + H)⁺: m/z calcd. 437.1978, found 437.1977.

Tert-butyl 5H-benzo[e]pyrido[2',1':2,3]imidazo[4,5-b]indole-7(6H)-carboxylate (5q). Yellow solid (120 mg, 67 % yield); mp 187-189 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm⁻¹): 1758, 1721, 1515, 1370, 1351, 1283, 1247, 1153, 1132, 1115, 1066, 763, 733; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.24 (d, J = 7.1 Hz, 1H), 8.18 (d, J = 7.5 Hz, 1H), 7.69 (d, J = 9.2 Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H), 7.19-7.10 (m, 3H), 6.74 (t, J = 6.9 Hz, 1H), 3.30 (t, J = 7.9 Hz, 2H), 3.11 (t, J = 8.0 Hz, 2H), 1.70 (s, 9H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 149.8, 147.6, 136.9, 134.1, 132.9 (2C), 130.98, 127.3, 127.0, 126.4, 126.2, 124.9, 123.0, 117.8, 113.5, 110.5, 85.4, 29.4, 28.4 (3CH₃), 24.2 (CH₃). HRMS (ESI): for C₂₂H₂₂N₃O₂ (M + H)⁺: m/z calcd. 360.1712, found 360.1716.

Tert-butylthiochromeno[4'',3'':4',5']pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-7(6H)-carboxylate (5r). Yellow solid (156 mg, 82% yield); mp 143-145 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm⁻¹): 1730, 1516, 1423, 1371, 1352, 1330, 1280, 1258, 1154, 1117, 760, 736; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.30 (d, J = 6.9 Hz, 1H), 8.41 (d, J = 7.5 Hz, 1H), 7.78 (d, J = 9.1 Hz, 1H), 7.37 (t, J = 8.0 Hz, 2H), 7.25 (q, J = 6.6 Hz, 2H), 6.86 (t, J = 6.7 Hz, 1H), 4.60 (s, 2H), 1.81 (s, 9H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 149.5, 147.8, 143.8, 139.6, 136.7, 129.8, 128.5, 127.3, 127.1, 126.8, 126.5 (2CH), 126.4, 123.6, 117.9, 110.8, 86.5, 28.4 (3CH₃), 25.7 (SCH₃). HRMS (ESI): for C₂₁H₂₀N₃O₂S (M + H)⁺: m/z calcd. 378.1276, found 378.1268.

Tert-butyl chromeno[4'',3'':4',5']pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-7(6H)-carboxylate (5s). Yellow solid (130 mg, 72% yield); mp 179-181 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm⁻¹): 1730, 1515, 1372, 1355, 1325, 1156, 1067, 1039, 861, 745; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.23 (d, J = 6.8 Hz, 1H), 7.99 (d, J = 8.3

Hz, 1H), 7.68 (d, $J = 9.2$ Hz, 1H), 7.20-7.12 (m, 2H), 7.06-7.01 (m, 1H), 6.89 (d, $J = 7.9$ Hz, 1H), 6.78 (t, $J = 6.9$ Hz, 1H), 5.67 (s, 2H), 1.70 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 153.4, 149.5, 148.6, 147.9, 131.3, 128.2, 126.3, 125.2, 123.7, 122.2, 119.1, 118.7, 118.0, 115.7, 111.7, 110.9, 86.4, 65.4 (OCH_2), 28.3 (3CH_3). HRMS (ESI): for $\text{C}_{21}\text{H}_{20}\text{N}_3\text{O}_3$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 362.1505, found 362.1508.

*Tert-butyl*2,3-bis(4-methoxyphenyl)-1*H*-pyrrolo[3',2':4,5]imidazo[1,2-*a*]pyridine-1-carboxylate (**5t**). Yellow solid (305 mg, 65% yield); mp 196-197 °C; $R_f = 0.35$ (cyclohexane/ethyl acetate 7/3); IR (film, cm^{-1}): 1718, 1515, 1355, 1326, 1198, 1178, 1152, 1099, 1072, 744; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.24 (d, $J = 7.7$ Hz, 1H), 7.67 (d, $J = 9.8$ Hz, 1H), 7.51 (d, $J = 8.5$ Hz, 2H), 7.29 (d, $J = 8.3$ Hz, 2H), 7.15–7.10 (m, 1H), 6.92 (d, $J = 8.4$ Hz, 2H), 6.80 (d, $J = 8.5$ Hz, 2H), 6.74 (t, $J = 6.9$ Hz, 1H), 3.84 (s, 3H), 3.75 (s, 3H), 1.24 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 159.6, 158.3, 150.1, 147.3, 138.5, 132.5 (2CH), 132.3, 129.9 (2CH), 126.9, 126.4, 125.6, 124.8, 123.2, 117.7, 116.6, 113.8 (2CH), 113.8 (2CH), 110.4, 84.3, 55.5, 55.2, 27.6 (3CH_3); HRMS (ESI): for $\text{C}_{28}\text{H}_{28}\text{N}_3\text{O}_4$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 470.2080, found 470.2056.

Tert-butyl 3-(4-methoxyphenyl)-7-(4-(trifluoromethyl)phenyl)-1*H*-pyrrolo[3',2':4,5]imidazo[1,2-*a*]pyridine-1-carboxylate (**5u**). Yellow solid (156 mg, 62% yield); mp 298-299 °C; $R_f = 0.3$ (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1728, 1616, 1510, 1390, 1326, 1295, 1252, 1178, 1161, 1125, 1070, 834; ^1H NMR (400 MHz, CDCl_3) δ (ppm): 9.06 (s, 1H), 7.56-7.52 (m, 2H), 7.29-7.26 (m, 5H), 7.00 (s, 1H), 6.93 (dd, $J_1 = 9.5$, $J_2 = 2.0$ Hz, 1H), 6.54-6.50 (m, 2H), 3.38 (s, 3H), 1.24 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ (ppm): 159.1, 146.7 (2C), 143.0, 141.6 (d, $J = 27$ Hz), 129.9, 127.6 (3CH), 127.4 (2CH), 126.1 (q, $J = 15$ Hz, 2CH), 125.5 (d, $J = 270$ Hz), 125.2 (2C), 123.5, 122.5, 119.8, 117.9, 116.2, 114.5 (2CH), 84.2, 55.5 (OCH_3), 25.3 (3CH_3); $^{19}\text{F}\{^1\text{H}\}$ NMR (188 MHz, CDCl_3) δ -62.50; HRMS (ESI): for $\text{C}_{28}\text{H}_{26}\text{F}_3\text{N}_3\text{O}_3$ ($\text{M} + \text{H}$) $^+$: m/z calcd. 508.1848, found 508.1843.

Tert-butyl 3,7-bis(4-methoxyphenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5v). Yellow solid (128 mg, 55% yield); mp 282-284 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1723, 1508, 1390, 1348, 1282, 1244, 1178, 1159, 1125, 1067, 833; ^1H NMR (400 MHz, CDCl_3) δ (ppm): 9.42 (s, 1H), 8.03 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 9.5 Hz, 1H), 7.56 (d, J = 8.3 Hz, 2H), 7.48 (s, 1H), 7.40 (d, J = 9.5 Hz, 1H), 7.05-6.96 (m, 4H), 3.86 (m, 6H), 1.71 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ (ppm): 159.4, 159.0, 156.9, 148.7, 146.7, 130.6 (2C), 130.2, 128.2 (3CH), 127.6 (2CH), 125.4 (2C), 124.3, 117.5, 117.4, 114.6 (2CH), 114.4 (2CH), 85.3, 55.5 (OCH_3), 55.4 (OCH_3), 28.3 (3CH_3). HRMS (ESI): for $\text{C}_{28}\text{H}_{28}\text{N}_3\text{O}_4$ ($\text{M} + \text{H}$): m/z calcd. 470.2080, found 470.2090.

Tert-butyl 3-(4-methoxyphenyl)-7-phenyl-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5w). Yellow solid (132 mg, 60% yield); mp 274-276 °C; R_f = 0.3 (cyclohexane/ethyl acetate 8/2); IR (film, cm^{-1}): 1722, 1510, 1393, 1349, 1244, 1178, 1158, 1124, 1066, 833, 755; ^1H NMR (400 MHz, CDCl_3) δ (ppm): 9.31 (s, 1H), 7.88 (d, J = 8.6 Hz, 2H), 7.59 (d, J = 9.5 Hz, 1H), 7.47 (d, J = 7.3 Hz, 2H), 7.33-7.20 (m, 5H), 6.85 (d, J = 8.6 Hz, 2H), 3.70 (s, 3H), 1.58 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ (ppm): 158.8, 148.5, 146.6, 137.9 (2C), 129.1, 129.0 (2CH), 127.5, 127.4 (2CH), 127.0 (2CH), 126.7, 125.3 (2C), 124.7, 124.0, 117.4, 117.2, 114.2 (2CH), 84.1, 55.3 (OCH_3), 28.2 (3CH_3). HRMS (ESI): for $\text{C}_{27}\text{H}_{26}\text{N}_3\text{O}_3$ ($\text{M} + \text{H}$): m/z calcd. 440.1974, found 440.1964.

Tert-butyl 3-(4-methoxyphenyl)-7-(1-(4-methoxyphenyl)vinyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-1-carboxylate (5x). Yellow solid (143 mg, 58% yield); mp 153-155 °C; R_f = 0.3 (cyclohexane/ethyl acetate 7/3); IR (film, cm^{-1}): 1724, 1608, 1511, 1393, 1347, 1248, 1179, 1154, 1108, 1032, 835; ^1H NMR (300 MHz, CDCl_3) δ (ppm): 9.25 (s, 1H), 8.02 (d, J = 8.6 Hz, 2H), 7.62 (d, J = 9.5 Hz, 1H), 7.51 (s, 1H), 7.33 (d, J = 8.6 Hz, 2H), 7.10 (d, J = 9.4 Hz, 1H), 7.00 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 5.48 (s, 1H), 5.45 (s, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 1.64 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ

(ppm): 159.8 (2C), 159.0 (2C), 148.6, 147.0, 146.2 (2C), 133.1, 129.4 (2CH), 127.6 (2CH), 125.8, 125.4, 125.2, 124.6, 118.0, 117.4, 116.8, 114.4 (2CH), 113.9 (2CH), 113.4, 85.2, 55.5 (OCH₃), 28.3 (3CH₃). HRMS (ESI): for C₃₀H₃₀N₃O₄ (M + H)⁺: *m/z* calcd. 496.2236, found 496.2241.

Tert-butyl 10-(3,4-dihydronaphthalen-1-yl)-5H-benzo[e]pyrido[2',1':2,3]imidazo[4,5-b]indole-7(6H)-carboxylate (5y). Yellow solid (321.8 mg, 66% yield); mp 206-207 °C; R_f = 0.4 (cyclohexane/ethyl acetate 7/3); IR (film, cm⁻¹): 1722, 1512, 1392, 1371, 1347, 1301, 1282, 1260, 1156, 1136, 765; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.24 (s, 1H), 8.21 (d, *J* = 7.5 Hz, 1H), 7.68 (d, *J* = 9.4 Hz, 1H), 7.34 (t, *J* = 7.9 Hz, 1H), 7.23-7.11 (m, 6H), 7.04 (d, *J* = 7.0 Hz, 1H), 6.22 (t, *J* = 4.6 Hz, 1H), 3.34 (t, *J* = 8.0 Hz, 2H), 3.13 (t, *J* = 7.9 Hz, 2H), 2.90 (t, *J* = 7.9 Hz, 2H), 2.50-2.44 (m, 2H), 1.67 (s, 9H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 149.6, 147.1, 137.2, 136.7 (2C), 134.8, 134.4, 132.9 (2C), 130.9, 128.7, 127.8, 127.4, 127.4, 127.1, 126.5, 126.4, 125.4, 125.3, 124.9, 124.6, 124.3, 116.7, 113.6, 85.5, 29.4, 28.4 (3CH₃), 28.3, 24.2, 23.6; HRMS (ESI): for C₃₂H₃₀N₃O₂ (M + H)⁺: *m/z* calcd. 488.2338, found 488.2344.

Tert-butyl 10-(2H-chromen-4-yl)chromeno[4'',3'':4',5']pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine-7(6H)-carboxylate (5z). Yellow solid (329 mg, 67% yield); mp 202-203 °C; R_f = 0.3 (cyclohexane/ethyl acetate 7/3); IR (film, cm⁻¹): 1730, 1447, 1356, 1330, 1315, 1290, 1065, 764, 748; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 9.28 (s, 1H), 8.02 (d, *J* = 7.2 Hz, 1H), 7.71 (d, *J* = 9.6 Hz, 1H), 7.25-7.12 (m, 3H), 7.07 (ddt, *J* = 9.2, 7.7, 1.4 Hz, 2H), 6.92 (ddd, *J* = 10.2, 7.7, 6.3 Hz, 3H), 5.96 (t, *J* = 3.9 Hz, 1H), 5.71 (s, 2H), 4.93 (d, *J* = 3.7 Hz, 2H), 1.69 (s, 9H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): ¹³C{¹H} NMR (101 MHz, CDCl₃) δ (ppm): 154.7, 151.5, 148.7, 147.1, 136.3, 133.9 (2C), 129.7 (2CH), 128.1, 125.6, 125.1, 125.1, 123.1, 122.2 (2C), 122.1, 121.4, 120.9, 119.0, 117.1, 116.4, 115.6, 109.7, 86.4, 65.2 (2CH₂), 28.15 (3CH₃). HRMS (ESI): for C₃₀H₂₆N₃O₄ (M + H)⁺: *m/z* calcd. 492.1923, found 492.1920.

General procedure to prepare compounds 5aa, 5cc, 5gg, and 5kk. In a 5 mL microwave reaction vial, compound **5a**, **5c**, **5g**, or **5k** (0.1 mmol, 1 equiv.) was dissolved in methanol and water (1:2 V/V) and trifluoroacetic acid (*ca.* 1 mg) was added to a solution. The reaction

mixture was subjected to microwave irradiation with stirring at 100 °C for 30 minutes. After the system had cooled down to room temperature, the reaction was diluted with H₂O, and extracted with ethyl acetate. The organic layer was washed with H₂O and brine and dried with Na₂SO₄, and the solvents were evaporated to give compounds **5aa**, **5cc**, **5gg** and **5kk** in excellent yields.

3-Phenyl-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine (5aa). Yellow solid (23 mg, 98% yield); mp 247-249 °C; IR (film, cm⁻¹): 1675, 1605, 1512, 1221, 1203, 846, 802, 755, 739, 724, 694; ¹H NMR (200 MHz, DMSO-*d*₆) δ (ppm): 11.70 (s, 1H), 8.47 (d, *J* = 6.6 Hz, 1H), 8.05 (d, *J* = 8.0 Hz, 2H), 7.62-7.57 (m, 2H), 7.38 (t, *J* = 7.7 Hz, 1H), 7.20-7.11 (m, 2H), 6.87 (t, *J* = 6.3 Hz, 1H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 145.0, 135.1, 134.5, 128.5 (2CH), 125.9, 124.8, 124.6 (2CH), 123.1, 122.2, 118.3, 116.9, 110.5, 109.8; HRMS (ESI): for C₁₅H₁₂N₃ (M + H)⁺: *m/z* calcd. 234.1031, found 234.1036.

3-(Phenanthren-3-yl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine (5cc). Yellow solid (32 mg, 96% yield); mp 259-261 °C; IR (film, cm⁻¹): 1511, 1496, 1341, 1302, 1261, 1221, 844, 804, 753, 736; ¹H NMR (200 MHz, DMSO-*d*₆) δ (ppm): 11.73 (s, 1H), 9.47 (s, 1H), 9.83 (d, *J* = 7.9 Hz, 1H), 8.47 (d, *J* = 6.8 Hz, 1H), 8.40-8.35 (m, 1H), 8.02-7.96 (m, 3H), 7.75-7.61 (m, 5H), 7.24-7.16 (m, 1H), 6.92 (t, *J* = 6.9 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ (ppm): ¹³C NMR{¹H} (75 MHz, CDCl₃) δ 145.2, 134.9, 133.9, 131.9, 130.2, 129.7, 129.3, 128.7, 128.5, 126.7, 126.7, 126.5, 126.1, 125.3, 124.2, 123.0, 122.8, 122.3, 119.3, 117.5, 117.1, 110.8, 109.9; HRMS (ESI): for C₂₃H₁₆N₃ (M + H)⁺: *m/z* calcd. 334.1344, found 334.1339.

3-(3,5-Dimethoxyphenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-a]pyridine (5gg). Yellow oil (27 mg, 92% yield); IR (film, cm⁻¹): 1607, 1589, 1511, 1457, 1339, 1203, 1154, 1063, 842, 768, 740; ¹H NMR (200 MHz, DMSO-*d*₆) δ (ppm): 11.57 (s, 1H), 8.41 (d, *J* = 7.5 Hz, 1H), 7.65-7.57 (m, 2H), 7.25 (d, *J* = 2.0 Hz, 2H), 7.19-7.10 (m, 1H), 6.87 (t, *J* = 7.0 Hz, 1H), 6.32-6.31 (m, 1H), 3.81 (s, 6H). ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): ¹³C NMR (75 MHz, CDCl₃) δ 160.7

(2C), 145.0 (C), 136.9 (C), 134.7, 125.8 (C), 122.9 (CH), 122.1 (CH), 118.9 (CH), 117.0 (CH), 116.0 (C), 109.8 (CH), 102.9 (2CH), 97.0 (CH), 55.1 (2OCH₃); HRMS (ESI): for C₁₇H₁₆N₃O₂ (M + H)⁺: *m/z* calcd. 294.1243, found 294.1241.

*3-(3,4,5-Trifluorophenyl)-1H-pyrrolo[3',2':4,5]imidazo[1,2-*a*]pyridine (5kk)*. Yellow solid (25 mg, 88% yield); mp 262-265 °C; IR (film, cm⁻¹): 1554, 1528, 1436, 1361, 1340, 1252, 1205, 1049, 1025, 1006, 762, 737. ¹H NMR (200 MHz, DMSO-*d*₆) δ (ppm): 11.92 (s, 1H); 8.48 (d, *J* = 6.7 Hz, 1H), 7.95-7.87 (m, 2H), 7.75 (s, 1H), 7.61 (d, *J* = 9.4 Hz, 1H), 7.22-7.14 (m, 1H), 6.89 (t, *J* = 6.7 Hz, 1H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ (ppm): 150.7 (dt, *J* = 250, 10 Hz, 2C), 145.4, 140.5 (d, *J* = 43 Hz), 134.4, 132.4 (d, *J* = 35 Hz), 127.4 (dt, *J* = 253, 15 Hz), 125.9, 123.2, 122.6, 199.8, 117.0, 110.1, 108.2 (d, *J* = 20.9 Hz, 2CH); ¹⁹F{¹H} NMR (188 MHz, CDCl₃) δ -136.18 (d, *J* = 21.8 Hz), -167.26 (t, *J* = 21.7 Hz); HRMS (ESI): for C₁₅H₅F₃N₃ (M + H)⁺: *m/z* calcd. 288.0749, found 288.0748.

General procedure for the one-pot cross-coupling between *N*-tosylhydrazones **1 and 2-chloro-3-nitroimidazo[1,2-*a*]pyridine **2**.** A 10 mL sealed tube under argon atmosphere was charged with *N*-tosylhydrazone (1.0 mmol, 1.0 equiv), 2-chloro-3-nitroimidazo[1,2-*a*]pyridine (1.0 mmol, 1.0 equiv.), Pd₂dba₃·CHCl₃ (2.5 mol %), and XPhos (5 mol %) in dioxane (4.0 mL), and the mixture was stirred at room temperature for 1 minute before the addition of LiOtBu (2.2 mmol, 2.2 equiv.). Then the tube was put into microwave and stirred at 110 °C for 30 minutes. Then MoO₂Cl₂(dmf)₂ (10 mol%), PPh₃ (4 equiv), were added, and the mixture was irradiated at 135 °C for 4 h. Finally, (Boc)₂O (1.3 mmol), DMAP (0.2 mmol), TEA (3 mmol), were added and the mixture was stirred at rt for 2 h. After cooling to r.t., DCM was added to the mixture. The solvents were evaporated under reduced pressure, and the crude residue was purified by column chromatography on silica gel using cyclohexane and ethyl acetate (7:3 to 3:7) as eluent to afford the desired product.

Biology

Cell culture and proliferation assays. HCT116 cancer cell line was obtained from the American type Culture Collection (ATCC, Rockville, MD) and was cultured according to the supplier's instructions. Human HCT116 colorectal carcinoma were grown in Gibco McCoy's 5A supplemented with 10% fetal calf serum (FCS) and 1% glutamine and were maintained at 37°C in a humidified atmosphere containing 5% CO₂. Cell viability was determined by a luminescent assay according to the manufacturer's instructions (Promega, Madison, WI, USA).

For IC₅₀ determination, the cells were seeded in 96-well plates (3 × 10³ cells/well) containing 100 μL of growth medium. After 24 h of culture, the cells were treated with the tested compounds at 10 different final concentrations. Each concentration was obtained from serial dilutions in culture medium starting from the stock solution. Control cells were treated with the vehicle. Experiments were performed in triplicate. After 72 h of incubation, 100 μL of CellTiter Glo Reagent was added for 15 min before recording luminescence with a spectrophotometric plate reader Polar Star Omega (BMG LabTech). The dose-response curves were plotted with Graph Prism software and the IC₅₀ values were calculated using the Graph Prism software from polynomial curves (four or five-parameter logistic equations). IC₅₀ values correspond to the concentration of test compound that causes a 50% decrease in fluorescence of drug-treated cells relative to untreated cells. Experiments were performed in triplicate. IC₅₀ values for all compounds were compared with this CA-4 and were measured the same day under the same conditions.

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at <http://pubs.acs.org>

- Copies of ¹H and ¹³C NMR spectra (PDF), X-ray data figures
- X-ray crystal structure for compound **5e** (CCDC 1920290) (CIF)
- X-ray crystal structure for compound **5s** (CCDC 1942283) (CIF)

- X-ray crystal structure for compound **5u** (CCDC 1942284) (CIF)

ACKNOWLEDGMENT

K. Zhang thanks the Chinese Scholarship Council for Ph.D. funding. The authors gratefully acknowledge support of this project by CNRS, University Paris-Sud and “La Ligue Contre le Cancer” throughout an “Equipe Labellisée 2014” grant. Our laboratory (Biocis UMR 8076 is a member of the laboratory of excellence LERMIT supported by a grant from ANR (ANR-10-LABX-33).

REFERENCES

1. (a) Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. *Nat. Rev. Cancer* **2004**, *4*, 253-265. (b) Jordan, M.; Wilson, L., Microtubule Dynamics. In *The Role of Microtubules in Cell Biology, Neurobiology, and Oncology*, Fojo, T., Ed. Humana Press: 2008; pp 47-81.
2. (a) Khelifi, I.; Naret, T.; Renko, D.; Hamze, A.; Bernadat, G.; Bignon, J.; Lenoir, C.; Dubois, J.; Brion, J.-D.; Provot, O.; Alami, M. Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors. *Eur J Med Chem* **2017**, *127*, 1025-1034. (b) Naret, T.; Bignon, J.; Bernadat, G.; Benchekroun, M.; Levaique, H.; Lenoir, C.; Dubois, J.; Pruvost, A.; Saller, F.; Borgel, D.; Manoury, B.; Leblais, V.; Darrigrand, R.; Apcher, S.; Brion, J.-D.; Schmitt, E.; Leroux, F. R.; Alami, M.; Hamze, A. A fluorine scan of a tubulin polymerization inhibitor isocombretastatin A-4: Design, synthesis, molecular modelling, and biological evaluation. *Eur. J. Med. Chem.* **2018**, *143*, 473-490. (c) Naret, T.; Khelifi, I.; Provot, O.; Bignon, J.; Levaique, H.; Dubois, J.; Souce, M.; Kasselouri, A.; Deroussent, A.; Paci, A.; Varela, P. F.; Gigant, B.; Alami, M.; Hamze, A. 1,1-Diheterocyclic Ethylenes Derived from Quinaldine and Carbazole as New Tubulin-Polymerization Inhibitors: Synthesis, Metabolism, and Biological Evaluation. *J. Med. Chem.* **2019**, *62*, 1902-1916. (d) Zheng, Y.; Sethi, R.; Mangala, L. S.; Taylor, C.; Goldsmith, J.; Wang, M.; Masuda, K.;

Karaminejadranjbar, M.; Mannion, D.; Miranda, F.; Herrero-Gonzalez, S.; Hellner, K.; Chen, F.; Alsaadi, A.; Albukhari, A.; Fotso, D. C.; Yau, C.; Jiang, D.; Pradeep, S.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Knapp, S.; Gray, N. S.; Campo, L.; Myers, K. A.; Dhar, S.; Ferguson, D.; Bast, R. C.; Sood, A. K.; von Delft, F.; Ahmed, A. A. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. *Nat. Commun.* **2018**, *9*, 476.

3. (a) Mita, M. M.; Sargsyan, L.; Mita, A. C.; Spear, M. Vascular-disrupting agents in oncology. *Expert Opin. Investig. Drugs* **2013**, *22*, 317-328. (b) Hinnen, P.; Eskens, F. A. Vascular disrupting agents in clinical development. *Br. J. Cancer* **2007**, *96*, 1159-1165.

4. Gaspari, R.; Prota, A. E.; Bargsten, K.; Cavalli, A.; Steinmetz, M. O. Structural Basis of cis- and trans-Combretastatin Binding to Tubulin. *Chem* **2017**, *2*, 102-113.

5. (a) Messaoudi, S.; Tréguier, B.; Hamze, A.; Provot, O.; Peyrat, J.-F.; De Losada, J. R.; Liu, J.-M.; Bignon, J.; Wdziejczak-Bakala, J.; Thoret, S.; Dubois, J.; Brion, J.-D.; Alami, M. Isocombretastatins A versus combretastatins A: the forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent. *J. Med. Chem.* **2009**, *52*, 4538-4542. (b) Hamze, A.; Giraud, A.; Messaoudi, S.; Provot, O.; Peyrat, J.-F.; Bignon, J.; Liu, J.-M.; Wdziejczak-Bakala, J.; Thoret, S.; Dubois, J.; Brion, J.-D.; Alami, M. Synthesis, biological evaluation of 1,1-diarylethylenes as a novel class of antimitotic agents. *ChemMedChem* **2009**, *4*, 1912-1924.

6. Bzeih, T.; Naret, T.; Hachem, A.; Jaber, N.; Khalaf, A.; Bignon, J.; Brion, J.-D.; Alami, M.; Hamze, A. A general synthesis of arylindoles and (1-arylvinyl)carbazoles via a one-pot reaction from *N*-tosylhydrazones and 2-nitro-haloarenes and their potential application to colon cancer. *Chem. Commun.* **2016**, *52*, 13027-13030.

7. (a) Cecile, E.-G.; Alain, G. Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines. *Mini Rev. Med. Chem.* **2007**, *7*, 888-899. (b) Kwong, H. C.; Chidan Kumar, C. S.;

- Mah, S. H.; Mah, Y. L.; Chia, T. S.; Quah, C. K.; Lim, G. K.; Chandraju, S. Crystal Correlation Of Heterocyclic Imidazo[1,2-a]pyridine Analogues and Their Anticholinesterase Potential Evaluation. *Sci. Rep.* **2019**, *9*, 926. (c) Bagdi, A. K.; Santra, S.; Monir, K.; Hajra, A. Synthesis of imidazo[1,2-a]pyridines: a decade update. *Chem. Commun.* **2015**, *51*, 1555-1575.
- (d) Zhai, X.; Wang, X.; Wang, J.; Liu, J.; Zuo, D.; Jiang, N.; Zeng, T.; Yang, X.; Jing, T.; Gong, P. Discovery and Optimization of Novel 5-Indolyl-7-arylimidazo[1,2-a]pyridine-8-carbonitrile Derivatives as Potent Antitubulin Agents Targeting Colchicine-binding Site. *Sci. Rep.* **2017**, *7*, 43398.
8. Richa, G.; Vijay, L.; Kamaldeep, P. Imidazo[1,2-a]pyridines: Promising Drug Candidate for Antitumor Therapy. *Curr. Top. Med. Chem.* **2016**, *16*, 3590-3616.
9. K. M. O'Connell; W. R. Galloway; Spring, D. R., The Basics of Diversity-Oriented Synthesis. In *Diversity-Oriented Synthesis*, Trabocchi, A., Ed. 2013; pp 1-26.
10. (a) For reviews on *N*-Tosylhydrazones, see Barluenga, J.; Valdés, C. Tosylhydrazones: new uses for classic reagents in palladium-catalyzed cross-coupling and metal-free reactions. *Angew. Chem. Int. Ed.* **2011**, *50*, 7486-7500. (b) Qiu, D.; Mo, F.; Zhang, Y.; Wang, J., Chapter Two - Recent Advances in Transition-Metal-Catalyzed Cross-Coupling Reactions With *N*-Tosylhydrazones. In *Adv. Organomet. Chem.*, Pedro, J. P., Ed. Academic Press: 2017; Vol. 67, pp 151-219. (c) Xiao, Q.; Zhang, Y.; Wang, J. Diazo Compounds and *N*-Tosylhydrazones: Novel Cross-Coupling Partners in Transition-Metal-Catalyzed Reactions. *Acc. Chem. Res.* **2012**, *46*, 236-247.
11. (a) Barluenga, J.; Moriel, P.; Valdés, C.; Aznar, F. *N*-Tosylhydrazones as Reagents for Cross-Coupling Reactions: A Route to Polysubstituted Olefins. *Angew. Chem.* **2007**, *119*, 5683-5686. (b) Brachet, E.; Hamze, A.; Peyrat, J.-F.; Brion, J.-D.; Alami, M. Pd-Catalyzed reaction of sterically hindered hydrazones with aryl halides: Synthesis of tetra-substituted olefins related to iso-combretastatin A4. *Org. Lett.* **2010**, *12*, 4042-4045. (c) Roche, M.;

- Hamze, A.; Provot, O.; Brion, J. D.; Alami, M. Synthesis of Ortho/Ortho '-Substituted 1,1-Diarylethylenes through Cross-Coupling Reactions of Sterically Encumbered Hydrazones and Aryl Halides. *J. Org. Chem.* **2013**, *78*, 445-454. (d) Roche, M.; Bignon, J.; Brion, J.-D.; Hamze, A.; Alami, M. Tandem One-Pot Palladium-Catalyzed Coupling of Hydrazones, Haloindoles, and Amines: Synthesis of Amino-N-vinylindoles and Their Effect on Human Colon Carcinoma Cells. *J. Org. Chem.* **2014**, *79*, 7583-7592. (e) Roche, M.; Salim, S. M.; Bignon, J.; Levaique, H.; Brion, J. D.; Alami, M.; Hamze, A. Palladium-catalyzed one-pot reaction of hydrazones, dihaloarenes, and organoboron reagents: Synthesis and cytotoxic activity of 1,1-diarylethylene derivatives. *J. Org. Chem.* **2015**, *80*, 6715-6727.
12. (a) Hamze, A.; Treguier, B.; Brion, J.-D.; Alami, M. Copper-catalyzed reductive coupling of tosylhydrazones with amines: A convenient route to [small alpha]-branched amines. *Org. Biomol. Chem.* **2011**, *9*, 6200-6204. (b) Aziz, J.; Brion, J.-D.; Hamze, A.; Alami, M. Copper Acetoacetate [Cu(acac)₂]/BINAP-Promoted Csp³-N Bond Formation via Reductive Coupling of *N*-Tosylhydrazones with Anilines. *Adv. Synth. Catal.* **2013**, *355*, 2417-2429. (c) Roche, M.; Frison, G.; Brion, J.-D.; Provot, O.; Hamze, A.; Alami, M. Csp²-N Bond Formation via Ligand-Free Pd-Catalyzed Oxidative Coupling Reaction of *N*-Tosylhydrazones and Indole Derivatives. *J. Org. Chem.* **2013**, *78*, 8485-8495.
13. Tschitschibabin, A. E. Zur Tautomerie des α -Amino-pyridins, IV. Mitteilung: Eine Darstellungsmethode des Pyrimidazols und seiner Homologen. *Ber. dtsh. Chem. Ges. A/B* **1925**, *58*, 1704-1706.
14. Cadogan, J. I. G.; Cameron-Wood, M. Reduction of Nitro-compounds by Triethyl Phosphite: A New Cyclisation Reaction. *Proc. Chem. Soc.* **1962**, , 361-361.
15. Shevlin, M.; Guan, X.; Driver, T. G. Iron-Catalyzed Reductive Cyclization of *o*-Nitrostyrenes Using Phenylsilane as the Terminal Reductant. *ACS Catal.* **2017**, *7*, 5518-5522.

16. Sanz, R.; Escribano, J.; Pedrosa, M. R.; Aguado, R.; Arnáiz, F. J. Dioxomolybdenum(VI)-Catalyzed Reductive Cyclization of Nitroaromatics. Synthesis of Carbazoles and Indoles. *Adv Synth Catal* **2007**, *349*, 713-718.
17. CCDC 1920290 (**5e**), CCDC 1942283 (**5s**), and CCDC 1942284 (**5t**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
18. Castiñeira Reis, M.; Marín-Luna, M.; Silva López, C.; Faza, O. N. Mechanism of the Molybdenum-Mediated Cadogan Reaction. *ACS Omega* **2018**, *3*, 7019-7026.
19. Perrin, D. D.; Armarego, W. L. F.; Perrin, D. R., *Purification of Laboratory Chemicals*. 2nd ed.; Pergamon Press: Oxford, 1980.
20. Creary, X.; Tam, W. W.; Albizati, K. F.; Stevens, R. V. Tosylhydrazone salt pyrolyses: phenyldiazomethanes. *Org. Synth.* **1986**, *64*, 207.
21. Zhang, B.-H.; Lei, L.-S.; Liu, S.-Z.; Mou, X.-Q.; Liu, W.-T.; Wang, S.-H.; Wang, J.; Bao, W.; Zhang, K. Zinc-promoted cyclization of tosylhydrazones and 2-(dimethylamino)malononitrile: an efficient strategy for the synthesis of substituted 1-tosyl-1H-pyrazoles. *Chem. Commun.* **2017**, *53*, 8545-8548.
22. Soussi, M. A.; Provot, O.; Bernadat, G.; Bignon, J.; Desravines, D.; Dubois, J.; Brion, J.-D.; Messaoudi, S.; Alami, M. IsoCombretaQuinazolines: Potent Cytotoxic Agents with Antitubulin Activity. *ChemMedChem* **2015**, *10*, 1392-1402.
23. Kerr, W. J.; Morrison, A. J.; Pazicky, M.; Weber, T. Modified Shapiro Reactions with Bismesitylmagnesium As an Efficient Base Reagent. *Org. Lett.* **2012**, *14*, 2250-2253.
24. García-Carrillo, M. A.; Guzmán, Á.; Díaz, E. Metal free coupling of heteroaryl N-tosylhydrazones and thiols: Efficient synthesis of sulfides. *Tetrahedron Lett.* **2017**, *58*, 1952-1956.

25. Brar, S. K.; Kumar, S.; Pandey, S. K.; Bhasin, K. K.; Wangoo, N.; Sharma, R. K. Fabrication of self-assembled imidazo[1,2-a]pyridine based materials: Understanding the impact of solvent and chemical modulation. *J. Mol. Liq.* **2018**, *254*, 208-215.
26. Stec, M. M.; Andrews, K. L.; Bo, Y.; Caenepeel, S.; Liao, H.; McCarter, J.; Mullady, E. L.; San Miguel, T.; Subramanian, R.; Tamayo, N.; Whittington, D. A.; Wang, L.; Wu, T.; Zalameda, L. P.; Zhang, N.; Hughes, P. E.; Norman, M. H. The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 4136-4142.